6-K 1 fresen_6k.txt FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2005 FRESENIUS MEDICAL CARE CORPORATION ----------------------------------------------- (Translation of registrant's name into English) Else-Kroner Strasse 1 61346 Bad Homburg Germany ---------------------------------------- (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ ] No [X] If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 This Report on Form 6-K shall be incorporated by reference in the prospectus, dated July 20, 2005 (the "Prospectus"), of Fresenius Medical Care AG (the "Company") included in the Company's Registration Statement (Registration No. 333-124759) on Form F-4 and shall be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by the Company with the U.S. Securities and Exchange Commission. The Company has received certain counter proposals to the proposals of the management board and the supervisory board. All counter proposals received by the Company during the period ended two weeks before the meeting date have been posted on our web site, www.fmc-ag.com. (By furnishing the Company's web site address in this report, the Company does not intend to incorporate any information on its web site into this report or into the Prospectus referred to above, and readers of this report should not consider any information on the Company's web site to be part of this report or the Prospectus). The following sets forth certain information relating to such counterproposals: Counter Proposals to the Proposed Conversion of Preference Shares into Ordinary ------------------------------------------------------------------------------- Shares (Agenda Item 1 of the Extraordinary General Meeting; Sole Agenda Item of ------------------------------------------------------------------------------- the Separate Meeting of Preference Shareholders) ------------------------------------------------ On August 12, 2005, the Company received a counterproposal from Citadel Equity Fund, Ltd., London. The counterproposal relates to both paragraph b) of the first resolution proposed for adoption at the extraordinary general meeting to be held August 30, 2005 and the sole resolution proposed for adoption at the separate meeting of preference shareholders. If approved, the counterproposal would reduce the conversion premium payable by holders of preference shares who elect to convert their shares into ordinary shares to (euro)9.75 per share. The text of the English translation of the counterproposal is as follows: b) Only preferred bearer shares without voting rights shall be converted into ordinary bearer shares with voting rights, which have been submitted to the Company in due time and in compliance with the conditions for the purpose of conversion together with the conversion declaration of the respective shareholder and a conversion premium in the amount of (euro)9.75 per preferred bearer share. Citadel Equity Fund Ltd., London has provided the following statement in support of its counterproposal: Grounds ------- The counter-motion is aimed at a reduction of the conversion premium to be paid by the holders of preferential shares upon acceptance of the exchange offer from (euro)12.25 to (euro)9.75. The conversion premium in the amount of (euro)12.25 initially proposed by the executive board and the supervisory board corresponds to 66% of the price difference of the stock prices of ordinary shares and of preferred shares and thus to a discount of approximately 10% on the stock price of the ordinary shares (in each case on the basis of the weighted average stock prices of both share classes of shares during the three-month-reference period prior to the ad hoc announcement). In our view, the amount of the proposed conversion premium of (euro)12.25 does not properly reflect the relative value of both classes of shares after the transformation of the legal form proposed as item 4 on the agenda and is, therefore, not appropriate, as the holders of preferred shares receive common shares in a partnership limited by shares (KGaA), and not in a stock corporation without a controlling main shareholder. 2 A reduction of the conversion premium to (euro)9.75 addresses our concerns. The proposed premium of (euro)9.75 increases the likelihood of success of the exchange offer. The reduction is in the interest of the Company, because it will greatly increase the chance of success of the preferred shares voting to approve the Conversion and will lead to greater acceptance by the holders of preferred shares in the Conversion. This will achieve the Company's stated goal of increasing liquidity of the common shares and improving DAX weighting. According, we believe that it is in the interest of both common and preferred shareholders and the Company that this counter proposal be approved. Two other counter proposals recommend that the conversion be effected without payment of any conversion premium. The Company expects that the counterproposal submitted by Citadel Equity Fund Ltd., London will be voted upon at the extraordinary general meeting and, if approved, will be voted upon at the separate meeting of preference shareholders, prior to submission of the agenda items set forth in the respective invitations to the meetings. On August 15, 2005, the Company issued a press release announcing that Fresenius AG, the owner of approximately 50.76% of the Company's ordinary shares, had informed the Company that it intends to vote its shares in favor of the counterproposal submitted by Citadel Equity Fund Ltd., London. A copy of the Company's press release is being filed as an exhibit to this report. If the counterproposal submitted by Citadel Equity Fund Ltd., London is approved, the original conversion proposal with a conversion premium of (euro)12.25 will not be considered at the meetings. Counter Proposal Relating to the Transformation of Legal Form (Agenda Item 4 of ------------------------------------------------------------------------------- the Extraordinary General Meeting) ---------------------------------- On August 16, 2005, the Company received a counter proposal from the Deutsche Schutzvereinigung fur Wertpapierbesitz (German Association for Private Investors - "DSW"). The full text of the English translation of the counter proposal is set forth below: The DSW (Deutsche Schutzvereinigung fur Wertpapierbesitz - German Association for Private Investors) will oppose the proposal of the Management Board and the Supervisory Board on the resolution on agenda item 4 b (Resolution on the transformation of Fresenius Medical Care AG into Fresenius Medical Care AG & Co. KGaA). With the voting rights that it is representing, the DSW will vote against the transformation of the legal form of the company into a Kommanditgesellschaft auf Aktien (Partnership Limited by Shares). DSW London has provided the following statement in support of its counterproposal: Reason: ------- The DSW explicitly appreciates the proposed conversion of non-voting preference shares into bearer ordinary shares on agenda item 1. The consolidation of both share classes will lead to an increased free float and, presumably, to an improved trading liquidity of the simplified share class of "Ordinary Shares." Furthermore the position in the stock index can be ensured. However, DSW explicitly disapproves the notion of a link between the merging of the two share classes and the proposed transformation of the legal form as per agenda item 4 b: From the perspective of the DSW, the legal form of an AG & Co. KGaA is only suitable to a limited extent for a listed public company. On the one hand the complicated corporate law requires explanation, especially for foreign investors. On the other hand and from the perspective of 3 the free float shareholders, this legal form has some controlling deficiencies that are not in the vested interest of good corporate governance. The Management Board of the KGaA is incumbent to a personally liable partner that in the case of Fresenius Medical Care is in turn another publicly traded stock corporation. In this case, the personally liable partner is FMC Management AG, which is a wholly-owned subsidiary of the parent company Fresenius AG. Among the Management Board of Fresenius AG and the Management Board of FMC Management AG, there are some members that serve on both boards. For the free float ordinary shareholders of Fresenius Medical Care this means that the Supervisory Board, which was elected by the free float ordinary shareholders, will not have rights regarding the competency of members of the Management Board of the managing FMC Management AG. With the proposed structure, the right to appoint and recall members of the Management Board according to the German Stock Corporation Act would then not be within the right of the Supervisory Board of the publicly listed company, but rather the right of the Supervisory Board of the management company, which is controlled by the parent company. This would result in a situation whereas the advantages that can be attributed to the conversion of the preference shares into ordinary shares for raising equity in the capital market and presumably the development of share value would in turn be disadvantaged by the legal form of a KGaA. It is notable, that the parent company is the only party that could compensate the controlling deficiencies related to the legal form of the KGaA as it controls the management company, whereas the free float shareholders and the Supervisory Board that has been duly elected thereof would thus have to accept less voting rights. This is the reason why the DSW will vote against the transformation of Fresenius Medical Care AG into an AG & Co. KGaA and requests other ordinary shareholders to follow this vote. EXHIBITS Exhibit 99. Press release issued August 15, 2005 4 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DATE: August 18, 2005 FRESENIUS MEDICAL CARE AKTIENGESELLSCHAFT By: /s/ BEN LIPPS --------------------------------------- Name: Dr. Ben Lipps Title: Chief Executive Officer and Chairman of the Management Board By: /s/ LAWRENCE A. ROSEN --------------------------------------- Name: Lawrence A. Rosen Title: Chief Financial Officer

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of August 2005

FRESENIUS MEDICAL CARE CORPORATION

(Translation of registrant’s name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

FRESENIUS MEDICAL CARE AG

TABLE OF CONTENTS

		Page
PART I
FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Statements of Income		1
	Consolidated Balance Sheets		3
	Consolidated Statements of Cash Flows		4
	Consolidated Statement of Shareholders’ Equity		5
	Notes To Consolidated Financial Statements		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		43
Item 4.	Controls and Procedures		44
PART II
OTHER INFORMATION
Item 1.	Legal Proceedings		45
Item 4.	Submission of Matters to a Vote of Security Holders		48
Item 6.	Exhibits		48
Signatures			49
Exhibit 10.1
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1

(i)

FRESENIUS MEDICAL CARE AG

PART I

FINANCIAL INFORMATION

ITEM 1

Financial Statements

Consolidated Statements of Income

For the three months ended June 30, 2005 and 2004

(unaudited)

(in thousands, except per share data)

		2005			2004
Net revenue:
	Dialysis Care		1,200,647			1,127,398
	Dialysis Products		473,040			424,904
			1,673,687			1,552,302
Costs of revenue:
	Dialysis Care		852,761			807,291
	Dialysis Products		233,903			219,869
			1,086,664			1,027,160
Gross profit			587,023			525,142
Operating expenses:
	Selling, general and administrative		335,775			298,363
	Research and development		13,143			14,101
Operating income			238,105			212,678
Other (income) expense:
	Interest income		(3,709	)		(2,846	)
	Interest expense		46,349			48,165
Income before income taxes and minority interest			195,465			167,359
Income tax expense			78,874			66,565
Minority interest			587			227
Net income			116,004			100,567
Basic income per Ordinary share			1.20			1.04
Fully diluted income per Ordinary share			1.19			1.03
Basic income per Preference share			1.22			1.06
Fully diluted income per Preference share			1.21			1.05

See accompanying notes to unaudited consolidated financial statements

FRESENIUS MEDICAL CARE AG

PART I

FINANCIAL INFORMATION

ITEM 1

Financial Statements

Consolidated Statements of Income

For the six months ended June 30, 2005 and 2004

(unaudited)

(in thousands, except per share data)

		2005			2004
Net revenue:
	Dialysis Care		2,363,108			2,185,148
	Dialysis Products		919,582			826,210
			3,282,690			3,011,358
Costs of revenue:
	Dialysis Care		1,691,107			1,573,974
	Dialysis Products		465,591			430,284
			2,156,698			2,004,258
Gross profit			1,125,992			1,007,100
Operating expenses:
	Selling, general and administrative		641,513			569,832
	Research and development		26,391			26,402
Operating income			458,088			410,866
Other (income) expense:
	Interest income		(5,954	)		(5,720	)
	Interest expense		90,881			97,742
Income before income taxes and minority interest			373,161			318,844
Income tax expense			148,517			126,262
Minority interest			1,169			906
Net income			223,475			191,676
Basic income per Ordinary share			2.31			1.98
Fully diluted income per Ordinary share			2.29			1.97
Basic income per Preference share			2.35			2.02
Fully diluted income per Preference share			2.33			2.01

See accompanying notes to unaudited consolidated financial statements

FRESENIUS MEDICAL CARE AG

Consolidated Balance Sheets

At June 30, 2005 (unaudited) and December 31, 2004

(in thousands, except share and per share data)

		2005		2004
		(Unaudited)
ASSETS
Current assets:
	Cash and cash equivalents	$	57,369	$	58,966
	Trade accounts receivable, less allowance for doubtful accounts of $182,140 in 2005 and $179,917 in 2004		1,452,808		1,462,847
	Accounts receivable from related parties		53,158		51,760
	Inventories		454,612		442,919
	Prepaid expenses and other current assets		237,840		244,093
	Deferred taxes		186,453		185,385
	Total current assets		2,442,240		2,445,970
	Property, plant and equipment, net		1,133,455		1,181,927
	Intangible assets		594,588		602,048
	Goodwill		3,437,251		3,445,152
	Deferred taxes		26,654		58,123
	Other assets		173,071		228,321
	Total assets	$	7,807,259	$	7,961,541
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
	Accounts payable	$	170,035	$	192,552
	Accounts payable to related parties		119,504		113,444
	Accrued expenses and other current liabilities		773,197		741,075
	Short-term borrowings		417,126		419,148
	Short-term borrowings from related parties		42,684		5,766
	Current portion of long-term debt and capital lease obligations		255,529		230,179
	Income tax payable		174,014		230,530
	Deferred taxes		14,728		5,159
	Total current liabilities		1,966,817		1,937,853
Long-term debt and capital lease obligations, less current portion			464,948		545,570
Other liabilities			101,089		156,122
Pension liabilities			99,109		108,125
Deferred taxes			300,401		282,261
Company-obligated mandatorily redeemable preferred securities of subsidiary Fresenius Medical Care Capital Trusts holding solely Company-guaranteed debentures of subsidiaries			1,208,004		1,278,760
Minority interest			18,306		18,034
	Total liabilities		4,158,674		4,326,725
Shareholders’ equity:
Preference shares, no par, €2.56 nominal value, 53,597,700 shares authorized, 26,454,805 issued and outstanding			70,400		69,878
Ordinary shares, no par, €2.56 nominal value, 70,000,000 shares authorized, issued and outstanding			229,494		229,494
Additional paid-in capital			2,754,825		2,746,473
Retained earnings			743,894		657,906
Accumulated other comprehensive loss			(150,028)		(68,935)
	Total shareholders’ equity		3,648,585		3,634,816
	Total liabilities and shareholders’ equity	$	7,807,259	$	7,961,541

See accompanying notes to unaudited consolidated financial statements

FRESENIUS MEDICAL CARE AG

Consolidated Statements of Cash Flows

For the six months ended June 30, 2005 and 2004

(unaudited)

(in thousands)

				2005		2004
Operating Activities:
	Net income			$	223,475	$	191,676
	Adjustments to reconcile net income to cash and cash equivalents provided by (used in) operating activities:
		Depreciation and amortization			121,328		113,827
		Change in deferred taxes, net			20,546		16,029
		Loss on sale of fixed assets			592		189
		Compensation expense related to stock options			832		802
		Cash inflow from Hedging			–		4,422
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			(41,561)		(1,244)
		Inventories			(29,743)		(6,428)
		Prepaid expenses, other current and non-current assets			(26,504)		37,559
		Accounts receivable from/ payable to related parties			2,339		(17,993)
		Accounts payable, accrued expenses and other current and non-current liabilities			36,659		9,047
		Income tax payable			(39,843)		2,986
			Net cash provided by operating activities		268,120		350,872
Investing Activities:
	Purchases of property, plant and equipment				(104,577)		(100,759)
	Proceeds from sale of property, plant and equipment				7,127		5,980
	Acquisitions and investments, net of cash acquired				(51,714)		(51,946)
		Net cash used in investing activities			(149,164)		(146,725)
Financing Activities:
	Proceeds from short-term borrowings				19,517		23,543
	Repayments of short-term borrowings				(46,474)		(26,987)
	Proceeds from short-term borrowings from related parties				39,572		50,000
	Repayments of short-term borrowings from related parties				–		(80,000)
	Proceeds from long-term debt				50,475		111,783
	Principal payments of long-term debt and capital lease obligations				(78,267)		(205,969)
	Increase of accounts receivable securitization program				27,235		68,002
	Proceeds from exercise of stock options				8,042		1,067
	Dividends paid				(137,487)		(122,106)
	Change in minority interest				909		(113)
		Net cash used in financing activities			(116,478)		(180,780)
Effect of exchange rate changes on cash and cash equivalents					(4,075)		(7,270)
Cash and Cash Equivalents:
	Net (decrease) increase in cash and cash equivalents				(1,597)		16,097
	Cash and cash equivalents at beginning of period				58,966		48,427
	Cash and cash equivalents at end of period			$	57,369	$	64,524

See accompanying notes to unaudited consolidated financial statements

FRESENIUS MEDICAL CARE AG

Consolidated Statement of Shareholders’ Equity

For the six months ended June 30, 2005 (unaudited) and year ended December 31, 2004

(in thousands, except share data)

															Accumulated Other Comprehensive
															Income (Loss)
			Preference Shares				Ordinary Shares
											Additional				Foreign				Minimum
			Number of		No Par		Number of		No Par		Paid in		Retained		Currency		Cash Flow		Pension
			Shares		Value		Shares		Value		Capital		Earnings		Translation		Hedges		Liability		Total
Balance at December 31, 2003				26,213,979	$	69,616		70,000,000	$	229,494	$	2,741,362	$	378,014	$	(146,246)	$	4,847	$	(33,407)	$	3,243,680
Proceeds from exercise of options				82,107		262						3,360										3,622
Compensation expense related to stock options												1,751										1,751
Dividends paid														(122,106)								(122,106)
Comprehensive income (loss)
	Net income													401,998								401,998
	Other comprehensive income (loss) related to:
		Cash flow hedges																(29,011)				(29,011)
		Foreign currency translation adjustment														144,784						144,784
		Minimum pension liability																		(9,902)		(9,902)
Comprehensive income																						507,869
Balance at December 31, 2004				26,296,086	$	69,878		70,000,000	$	229,494	$	2,746,473	$	657,906	$	(1,462)	$	(24,164)	$	(43,309)	$	3,634,816
Proceeds from exercise of options				158,719		522						7,520										8,042
Compensation expense related to stock options												832										832
Dividends paid														(137,487)								(137,487)
Comprehensive income (loss)
	Net income													223,475								223,475
	Other comprehensive income (loss) related to:
		Cash flow hedges																4,568				4,568
		Foreign currency translation adjustment														(85,661)						(85,661)
Comprehensive income																						142,382
Balance at June 30, 2005				26,454,805	$	70,400		70,000,000	$	229,494	$	2,754,825	$	743,894	$	(87,123)	$	(19,596)	$	(43,309)	$	3,648,585

See accompanying notes to unaudited consolidated financial statements

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(in thousands, except share and per share data)

1. The Company and Basis of Presentation

The Company

Fresenius Medical Care AG (“FMC-AG” or the “Company”), a German stock corporation (Aktiengesellschaft), is the world’s largest integrated provider of kidney dialysis services and manufacturer and distributor of products and equipment for the treatment of end-stage renal disease. In the United States, the Company also performs clinical laboratory testing and provides perfusion, therapeutic apheresis and autotransfusion services.

The Company announced that it intends to change the Company’s current legal form as an Aktiengesellschaft (“AG”) to a KGaA, which is a German partnership limited by shares (the “Transformation of Legal Form”). The Company as a KGaA will be the same legal entity under German law, rather than a successor to the AG. Fresenius Medical Care Management AG, a subsidiary of Fresenius AG, the ultimate parent of FMC-AG, will be the general partner of the Company. The Transformation of Legal Form is subject to approval by the Company’s ordinary shareholders which will be voted upon by the ordinary shareholders at the Extraordinary General Meeting (“EGM”) to be held on August 30, 2005.

The Company also announced that it intends to offer its preference shareholders the opportunity to convert their preference shares into ordinary shares on a one-to-one basis pursuant to a conversion offer to be conducted after the EGM. Preference shareholders who decide to convert their shares will be required to pay a premium and will lose their preferential dividend rights. The conversion is subject to approval of the ordinary shareholders at the EGM and also subject to approval by a separate vote of the Company’s preference shareholders which will be voted upon at a separate meeting of the preference shareholders immediately following the EGM on August 30, 2005 or, if necessary, on August 31, 2005.

Basis of Presentation

a) Basis of Consolidation

The consolidated financial statements at June 30, 2005 and for the three-and six-month periods ended June 30, 2005 and 2004 in this report are unaudited and should be read in conjunction with the consolidated financial statements in the Company’s 2004 Annual Report on Form 20-F. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature.

The results of operations for the three- and six-month periods ended June 30, 2005 are not necessarily indicative of the results of operations for the year ending December 31, 2005.

b) Classifications

Certain items in the prior year’s comparative consolidated financial statements have been reclassified to conform with the current year’s presentation.

2. Proposed acquisitions

On May 4th, 2005, the Company entered into a definitive merger agreement for the acquisition of Renal Care Group, Inc. (“RCG”) for an all cash purchase price of approximately $3.5 billion. At March 31, 2005, RCG provided dialysis and ancillary services to over 30,400 patients through more than 425 owned outpatient dialysis centers in 34 states within the United States, in addition to providing acute dialysis services to more than 210 hospitals. Completion of the acquisition is subject to governmental approvals (including termination or expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

amended, the “Act”), third-party consents, and approval by RCG’s stockholders in a vote currently scheduled for August 24, 2005. On June 15, 2005, the Company announced it had received a second request from the U.S. Federal Trade Commission (“FTC”) for additional information in connection with this proposed acquisition. The effect of this request, which was anticipated when the acquisition was announced, is to extend the waiting period imposed by the Act until 30 days after the Company and RCG have substantially complied with the request, unless that period is voluntarily extended by the parties or is terminated by the FTC.

In connection with the proposed acquisition, the Company has entered into a commitment letter pursuant to which Bank of America, N.A. (“BofA”) and Deutsche Bank AG (“DB”) have agreed, subject to certain conditions, to underwrite an aggregate $5.0 billion in principal amount of term and revolving loans to be syndicated to other financial institutions. BofA and DB also must approve any material modification to the merger agreement and any waiver of any material conditions precedent under that agreement. The financing will be available to the Company, among other uses, to pay the purchase price and related expenses for the proposed acquisition of RCG, to refinance outstanding indebtedness under our existing senior credit facility (see Note 4) and certain indebtedness of RCG, and to utilize for general corporate purposes. In conjunction with the proposed acquisition of Renal Care Group, Inc. and the forecasted variable rate interest payments for its financing, the Company entered into forward starting interest rate swaps in the notional amount of $1,500,000 in June and July 2005. These instruments, designated as cash flow hedges, effectively convert forecasted variable rate interest payments into fixed rate interest payments with an average fixed rate of 4.185% plus an applicable margin. These swaps are denominated in U.S. dollars and expire at various dates in 2010 and 2011.

3. Inventories

As of June 30, 2005 and December 31, 2004, inventories consisted of the following:

		June 30,		December 31,
		2005		2004
Raw materials and purchased components		$	98,240	$	90,268
Work in process			32,932		36,586
Finished goods			243,777		240,296
Health care supplies			79,663		75,769
	Inventories	$	454,612	$	442,919

4. Short-term Borrowings, Long-term Debt and Capital Lease Obligations

As of June 30, 2005 and December 31, 2004, short-term borrowings consisted of the following:

	June 30,		December 31,
	2005		2004
Borrowings under lines of credit	$	54,126	$	83,383
Accounts receivable facility		363,000		335,765
	$	417,126	$	419,148

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

At June 30, 2005 and December 31, 2004, long-term debt and capital lease obligations consisted of the following:

	June 30,			December 31,
	2005			2004
Senior Credit Agreement		478,100			484,500
Euro Notes		155,382			175,030
Capital lease obligations		4,710			6,987
Other		82,285			109,232
		720,477			775,749
Less current maturities		(255,529	)		(230,179	)
		464,948			545,570

5. Stock Options

The Company accounts for its stock option plans using the intrinsic value method in accordance with the provisions of Accounting Principles Board (“APB”) Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations, as allowed by SFAS No. 123, Accounting for Stock-Based Compensation, subject to complying with the additional disclosure requirements of SFAS No. 123 as amended by SFAS No. 148, Accounting for Stock-Based Compensation – Transition and Disclosure – an amendment of FASB Statement No. 123. As such, compensation expense is recorded only if the current market price of the underlying stock exceeds the exercise price on the measurement date. For stock incentive plans which are performance based, the Company recognizes compensation expense over the vesting periods, based on the then current market values of the underlying stock.

As of June 30, 2005, the Company had 4,455,273 stock options outstanding.

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock based employee compensation.

			For the Three Months						For the Six Months
			Ended June 30,						Ended June 30,
			2005			2004			2005			2004
Net income:
	As reported		$	116,004		$	100,567		$	223,475		$	191,676
	Add: Stock-based employee compensation expense included in reported net income, net of related tax effects			408			426			832			802
	Deduct: Total stock-based employee compensation expense determined under fair value method for all awards, net of related tax effects			(2,506	)		(1,992	)		(5,013	)		(4,001	)
	Pro forma		$	113,906		$	99,001		$	219,294		$	188,477
Basic net income per:
	Ordinary share
		As reported	$	1.20		$	1.04		$	2.31		$	1.98
		Pro forma	$	1.18		$	1.02		$	2.27		$	1.95
	Preference share
		As reported	$	1.22		$	1.06		$	2.35		$	2.02
		Pro forma	$	1.20		$	1.04		$	2.31		$	1.99
Fully diluted net income per:
	Ordinary share
		As reported	$	1.19		$	1.03		$	2.29		$	1.97
		Pro forma	$	1.17		$	1.01		$	2.25		$	1.94
	Preference share
		As reported	$	1.21		$	1.05		$	2.33		$	2.01
		Pro forma	$	1.19		$	1.03		$	2.29		$	1.98

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

The following tables contain reconciliations of the numerators and denominators of the basic and diluted earnings per share computations for the three- and six-month periods ended June 30, 2005 and 2004.

		For the Three Months Ended
		June 30,
		2005		2004
Numerators:
Net income		$	116,004	$	100,567
less:
	Dividend preference on Preference shares		496		471
Income available to all classes of shares		$	115,508	$	100,096
Denominators:
Weighted average number of:
Ordinary shares outstanding			70,000,000		70,000,000
Preference shares outstanding			26,406,901		26,230,568
Total weighted average shares outstanding			96,406,901		96,230,568
Potentially dilutive Preference shares			763,580		516,958
Total weighted average shares outstanding assuming dilution			97,170,481		96,747,526
Total weighted average Preference shares outstanding assuming dilution			27,170,481		26,747,526
Basic income per Ordinary share		$	1.20	$	1.04
Plus preference per Preference shares			0.02		0.02
Basic income per Preference share		$	1.22	$	1.06
Fully diluted income per Ordinary share		$	1.19	$	1.03
Plus preference per Preference shares			0.02		0.02
Fully diluted income per Preference share		$	1.21	$	1.05

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

		For the Six Months Ended
		June 30,
		2005		2004
Numerators:
Net income		$	223,475	$	191,676
less:
	Dividend preference on Preference shares		1,007		960
Income available to all classes of shares		$	222,468	$	190,716
Denominators:
Weighted average number of:
Ordinary shares outstanding			70,000,000		70,000,000
Preference shares outstanding			26,368,725		26,223,134
Total weighted average shares outstanding			96,368,725		96,223,134
Potentially dilutive Preference shares			657,368		409,882
Total weighted average shares outstanding assuming dilution			97,026,093		96,633,016
Total weighted average Preference shares outstanding assuming dilution			27,026,093		26,633,016
Basic income per Ordinary share		$	2.31	$	1.98
Plus preference per Preference shares			0.04		0.04
Basic income per Preference share		$	2.35	$	2.02
Fully diluted income per Ordinary share		$	2.29	$	1.97
Plus preference per Preference shares			0.04		0.04
Fully diluted income per Preference share		$	2.33	$	2.01

6. Employee Benefit Plans

The Company currently has two principal pension plans, one for German employees, the other covering employees in the United States. Plan benefits are generally based on years of service and final salary. Consistent with predominant practice in Germany, the Company’s pension obligations in Germany are unfunded. Each year FMCH contributes at least the minimum required by the Employee Retirement Income Security Act of 1974, as amended. There is no minimum funding requirement for FMCH for the defined benefit pension plan in 2005. FMCH made $5,000 in contributions in the second quarter 2005 and $10,000 cumulatively as of June 30, 2005 and at this time expects to voluntarily contribute $20,000 in total during

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

2005. The following table provides the calculations of net periodic benefit cost for the three- and six-month periods ended June 30, 2005 and 2004.

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2005			2004			2005			2004
Components of net period benefit cost:
Service cost	$	1,286		$	1,008		$	2,616		$	2,048
Interest cost		3,982			3,653			8,000			7,333
Expected return on plan assets		(3,085	)		(2,325	)		(6,170	)		(4,650	)
Net amortization		1,600			1,175			3,200			2,350
Net periodic benefit cost	$	3,783		$	3,511		$	7,646		$	7,081

7. Commitments and Contingencies

Legal Proceedings

Commercial Litigation

The Company was formed as a result of a series of transactions pursuant to the Agreement and Plan of Reorganization (the “Merger”) dated as of February 4, 1996 by and between W.R. Grace & Co. and Fresenius AG. At the time of the Merger, a W.R. Grace & Co. subsidiary known as W.R. Grace & Co.-Conn. had, and continues to have, significant potential liabilities arising out of product-liability related litigation, pre-Merger tax claims and other claims unrelated to NMC, which was W.R. Grace & Co.’s dialysis business prior to the Merger. In connection with the Merger, W.R. Grace & Co.-Conn. agreed to indemnify the Company, FMCH, and NMC against all liabilities of W.R. Grace & Co., whether relating to events occurring before or after the Merger, other than liabilities arising from or relating to NMC’s operations. W.R. Grace & Co. and certain of its subsidiaries filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Grace Chapter 11 Proceedings”) on April 2, 2001.

Pre-Merger tax claims or tax claims that would arise if events were to violate the tax-free nature of the Merger, could ultimately be the Company’s obligation. In particular, W. R. Grace & Co. has disclosed in its filings with the Securities and Exchange Commission that: its tax returns for the 1993 to 1996 tax years are under audit by the Internal Revenue Service (the “Service”); W. R. Grace & Co. has received the Service’s examination report on tax periods 1993 to 1996; that during those years W.R. Grace & Co. deducted approximately $122,100 in interest attributable to corporate owned life insurance (“COLI”) policy loans; that W.R. Grace & Co. has paid $21,200 of tax and interest related to COLI deductions taken in tax years prior to 1993; that a U.S. District Court ruling has denied interest deductions of a taxpayer in a similar situation. In October 2004, W.R. Grace & Co. obtained bankruptcy court approval to settle its COLI claims with the Service. In January 2005, W.R. Grace & Co., FMCH and Sealed Air Corporation executed a settlement agreement with respect to the Service’s COLI-related claims and other tax claims. On April 14, 2005, W.R. Grace & Co. paid the Service approximately $90 million in connection with taxes owed for the tax periods 1993 to 1996 pursuant to a bankruptcy court order directing W.R. Grace & Co. to make such payment. Subject to certain representations made by W.R. Grace & Co., the Company and Fresenius AG, W.R. Grace & Co. and certain of its affiliates had agreed to indemnify the Company against this and other pre-Merger and Merger-related tax liabilities.

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

and by the asbestos creditors’ committees on behalf of the W.R. Grace & Co. bankruptcy estate in the Grace Chapter 11 Proceedings, alleging among other things that the Merger was a fraudulent conveyance, violated the uniform fraudulent transfer act and constituted a conspiracy. All such cases have been stayed and transferred to or are pending before the U.S. District Court as part of the Grace Chapter 11 Proceedings.

In 2003, the Company reached agreement with the asbestos creditors’ committees on behalf of the W.R. Grace & Co. bankruptcy estate and W.R. Grace & Co. in the matters pending in the Grace Chapter 11 Proceedings for the settlement of all fraudulent conveyance and tax claims against it and other claims related to the Company that arise out of the bankruptcy of W.R. Grace & Co. Under the terms of the settlement agreement as amended (the “Settlement Agreement”), fraudulent conveyance and other claims raised on behalf of asbestos claimants will be dismissed with prejudice and the Company will receive protection against existing and potential future W.R. Grace & Co. related claims, including fraudulent conveyance and asbestos claims, and indemnification against income tax claims related to the non-NMC members of the W.R. Grace & Co. consolidated tax group upon confirmation of a W.R. Grace & Co. bankruptcy reorganization plan that contains such provisions. Under the Settlement Agreement, the Company will pay a total of $115,000 to the W.R. Grace & Co. bankruptcy estate, or as otherwise directed by the Court, upon plan confirmation. No admission of liability has been or will be made. The Settlement Agreement has been approved by the U.S. District Court. Subsequent to the Merger, W.R. Grace & Co. was involved in a multi-step transaction involving Sealed Air Corporation (“Sealed Air”, formerly known as Grace Holding, Inc.). The Company is engaged in litigation with Sealed Air to confirm its entitlement to indemnification from Sealed Air for all losses and expenses incurred by the Company relating to pre-Merger tax liabilities and Merger-related claims. Under the Settlement Agreement, upon confirmation of a plan that satisfies the conditions of the Company’s payment obligation, this litigation will be dismissed with prejudice.

On April 4, 2003, FMCH filed a suit in the U.S. District Court for the Northern District of California, Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that FMCH does not infringe on patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against FMCH for alleged infringement of Baxter’s patents. In general, the alleged patents concern touch screens, conductivity alarms, power failure data storage, and balance chambers for hemodialysis machines. Baxter has filed counterclaims against FMCH seeking monetary damages and injunctive relief, and alleging that FMCH willfully infringed on Baxter’s patents. FMCH believes its claims are meritorious, although the ultimate outcome of any such proceedings cannot be predicted at this time and an adverse result could have a material adverse effect on the Company’s business, financial condition, and results of operations.

Other Litigation and Potential Exposures

In April 2005, FMCH received a subpoena from the U.S. Department of Justice, Eastern District of Missouri, in connection with a joint civil and criminal investigation. The subpoena requires production of a broad range of documents relating to the FMCH’s operations, with specific attention to documents related to clinical quality programs, business development activities, medical director compensation and physician relations, joint ventures and anemia management programs. We are cooperating with the government’s requests for information. An adverse determination in this investigation could have a material adverse effect on our business, financial condition and results of operations.

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

and vitamin D therapies. The Company is cooperating with the government’s requests for information. While the Company believes that it has complied with applicable laws relating to PTH testing and use of vitamin D therapies, an adverse determination in this investigation could have a material adverse effect on the Company’s business, financial condition, and results of operations.

From time to time, the Company is a party to or may be threatened with other litigation, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company’s defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.

The Company, like other health care providers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. The Company must also comply with the Anti-Kickback Statute, the False Claims Act, the Stark Statute, and other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company’s or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “whistle blower” actions. By virtue of this regulatory environment, as well as our corporate integrity agreement with the U.S. federal government, the Company’s business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, investigative demands, subpoenas, other inquiries, claims and litigation relating to our compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal.

The Company operates many facilities throughout the United States. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of these employees. On occasion, the Company may identify instances where employees, deliberately or inadvertently, have submitted inadequate or false billings. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Statute and the False Claims Act, among other laws.

Physicians, hospitals and other participants in the health care industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker’s compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company’s reputation and business.

The Company has also had claims asserted against it and has had lawsuits filed against it relating to businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company’s reputation and business.

Accrued Special Charge for Legal Matters

At December 31, 2001, the Company recorded a pre-tax special charge of $258,159 to reflect anticipated expenses associated with the defense and resolution of pre-Merger tax claims, Merger-related claims, and commercial insurer claims. The costs associated with the Settlement Agreement and settlements with insurers have been charged against this accrual. While the Company believes that its remaining accruals reasonably estimate its currently anticipated costs related to the continued defense and resolution of the remaining matters, no assurances can be given that its actual costs incurred will not exceed the amount of this accrual.

8. Business Segment Information

The Company has identified three business segments, North America, International, and Asia Pacific, which were determined based upon how the Company manages its businesses. All segments are primarily engaged in providing dialysis services and manufacturing and distributing products and equipment for the treatment of end-stage renal disease. Additionally, the North America segment engages in performing clinical laboratory testing and providing perfusion, therapeutic apheresis and autotransfusion services. For management responsibility purposes, the Company transferred its Mexico operations from its International segment to its North American segment beginning January 1, 2005 and reclassified the Mexico operations and assets for the comparative interim periods of 2004. The Company has aggregated the International and Asia Pacific operating segments as “International”. The segments are aggregated due to their similar economic characteristics. These characteristics include the same products sold, the same type patient population, similar methods of distribution of products and services and similar economic environments.

Management evaluates each segment using a measure that reflects all of the segment’s controllable revenues and expenses. Management believes that the most appropriate measure in this regard is operating income which measures the Company’s source of earnings. Financing is a corporate function, which the Company’s segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measure. The Company also regards income taxes to be outside the segment’s control.

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

Information pertaining to the Company’s business segments for the three-and six-month periods ended June 30, 2005 and 2004 is set forth below:

		North
		America		International		Corporate		Total
Six months ended June 30, 2005
	Net revenue external customers	$	2,215,137	$	1,067,553	$	–	$	3,282,690
	Inter-segment revenue		605		25,975		(26,580)		–
	Total net revenue		2,215,742		1,093,528		(26,580)		3,282,690
	Depreciation and amortization		(68,589)		(51,764)		(975)		(121,328)
	Operating income (EBIT)		303,502		174,169		(19,583)		458,088
	Segment assets		5,561,917		2,224,986		20,356		7,807,259
	Capital expenditures and acquisitions		92,224		64,014		53		156,291
Six months ended June 30, 2004
	Net revenue external customers	$	2,063,017	$	948,341	$	–	$	3,011,358
	Inter-segment revenue		804		18,439		(19,244)		–
	Total net revenue		2,063,821		966,780		(19,244)		3,011,358
	Depreciation and amortization		(63,827)		(49,037)		(963)		(113,827)
	Operating income (EBIT)		282,901		145,929		(17,965)		410,866
	Segment assets		5,501,977		2,123,392		43,967		7,669,336
	Capital expenditures and acquisitions(1)		94,691		57,860		154		152,705
Three months ended June 30, 2005
	Net revenue external customers	$	1,126,953	$	546,734	$	–	$	1,673,687
	Inter-segment revenue		375		13,790		(14,165)		–
	Total net revenue		1,127,328		560,524		(14,165)		1,673,687
	Depreciation and amortization		(34,804)		(26,336)		(477)		(61,617)
	Operating income (EBIT)		157,217		92,019		(11,131)		238,105
	Capital expenditures and acquisitions		53,804		36,951		24		90,779
Three months ended June 30, 2004
	Net revenue external customers	$	1,060,416	$	491,886	$	–	$	1,552,302
	Inter-segment revenue		618		9,243		(9,862)		–
	Total net revenue		1,061,034		501,130		(9,862)		1,552,302
	Depreciation and amortization		(32,420)		(24,116)		(450)		(56,986)
	Operating income (EBIT)		147,144		74,858		(9,324)		212,678
	Capital expenditures and acquisitions		46,261		21,278		–		67,539

(1) International acquisitions exclude $8,224 of non-cash acquisitions in 2004

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2005		2004		2005		2004
Reconciliation of Measures to Consolidated Totals
	Total operating income of reporting segments	$	249,236	$	222,003	$	477,671	$	428,831
	Corporate expenses		(11,131)		(9,325)		(19,583)		(17,965)
	Interest expense		3,709		2,846		5,954		5,720
	Interest income		(46,349)		(48,165)		(90,881)		(97,742)
	Total income before income taxes and minority interest	$	195,465	$	167,359	$	373,161	$	318,844
	Depreciation and amortization
	Total depreciation and amortization of reporting segments		(61,140)		(56,536)		(120,353)		(112,864)
	Corporate depreciation and amortization		(477)		(450)		(975)		(963)
	Total depreciation and amortization	$	(61,617)	$	(56,986)	$	(121,328)	$	(113,827)

9. Supplementary Cash Flow Information

The following additional information is provided with respect to the consolidated statements of cash flows:

		Six Months Ended
		June 30,
		2005		2004
Supplementary cash flow information:
	Cash paid for interest	$	91,062	$	96,217
	Cash paid for income taxes	$	156,029	$	102,917
Supplemental disclosures of cash flow information:
	Details for acquisitions:
	Assets acquired	$	52,952	$	83,764
	Liabilities assumed		6,019		11,062
	Minorities		(5,017)		–
	Notes assumed in connection with acquisition		–		8,224
	Cash paid		51,950		64,478
	Less cash acquired		236		12,532
	Net cash paid for acquisitions	$	51,714	$	51,946

10. Supplemental Condensed Combining Information

FMC Trust Finance S.à.r.l. Luxembourg and FMC Trust Finance S.à.r.l. Luxembourg-III, each of which is a wholly-owned subsidiary of the Company, are the obligors on senior subordinated debt securities

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

which are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated basis, by the Company and by Fresenius Medical Care Deutschland GmbH (“D-GmbH”), a wholly-owned subsidiary of the Company, and by FMCH, a substantially wholly-owned subsidiary of the Company (D-GmbH and FMCH being “Guarantor Subsidiaries”). In December 2004, the Company assumed the obligations of its wholly owned subsidiaries as the issuer of senior subordinated indebtedness held by Fresenius Medical Care Capital Trust III and Fresenius Medical Care Capital Trust V, respectively. The following combining financial information for the Company is as of June 30, 2005 and December 31, 2004 and for the six-months ended June 30, 2005 and 2004, segregated between the Company, D-GmbH, FMCH and each of the Company’s other businesses (the “Non-Guarantor Subsidiaries”). For purposes of the condensed combining information, the Company and the Guarantor Subsidiaries carry their investments under the equity method. Other (income) expense includes income (loss) related to investments in consolidated subsidiaries recorded under the equity method for purposes of the condensed combining information. In addition, other (income) expense includes income and losses from profit and loss transfer agreements as well as dividends received. Separate financial statements and other disclosures concerning D-GmbH and FMCH are not presented herein because management believes that they are not material to investors.

		For the Six Months Period Ended June 30, 2005
				Guarantor Subsidiaries
								Non-Guarantor		Combining		Combined
		FMC-AG		D-GmbH		FMCH		Subsidiaries		Adjustment		Total
Net revenue		$	–	$	528,013	$	–	$	3,393,768	$	(639,091)	$	3,282,690
Cost of revenue			–		326,830		–		2,462,021		(632,153)		2,156,698
	Gross profit		–		201,183		–		931,747		(6,938)		1,125,992
Operating expenses:
	Selling, general and administrative		28,278		68,004		–		481,786		63,445		641,513
	Research and development		1,681		16,534		–		8,176		–		26,391
Operating (loss) income			(29,959)		116,645		–		441,785		(70,383)		458,088
Other (income) expense:
	Interest, net		16,246		7,060		25,760		53,784		(17,923)		84,927
	Other, net		(293,469)		67,349		(148,325)		–		374,445		–
Income before income taxes and minority interest			247,264		42,236		122,565		388,001		(426,905)		373,161
	Income tax expense (benefit)		23,789		39,478		(10,304)		121,060		(25,506)		148,517
Income (loss) before minority interest			223,475		2,758		132,869		266,941		(401,399)		224,644
Minority interest			–		–		–		–		1,169		1,169
Net income (loss)		$	223,475	$	2,758	$	132,869	$	266,941	$	(402,568)	$	223,475

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

		For the Six Months Period Ended June 30, 2004
				Guarantor Subsidiaries
								Non-Guarantor		Combining		Combined
		FMC-AG		D-GmbH		FMCH		Subsidiaries		Adjustment		Total
Net revenue		$	–	$	463,495	$	–	$	3,081,566	$	(533,703)	$	3,011,358
Cost of revenue			–		300,662		–		2,235,340		(531,744)		2,004,258
	Gross profit		–		162,833		–		846,226		(1,959)		1,007,100
Operating expenses:
	Selling, general and administrative		14,600		72,183		–		482,863		186		569,832
	Research and development		1,203		16,785		–		8,414		–		26,402
Operating (loss) income			(15,804)		73,865		–		354,950		(2,145)		410,866
Other (income) expense:
	Interest, net		15,805		7,033		31,162		52,668		(14,646)		92,022
	Other, net		(240,830)		42,602		(135,410)		–		333,638		–
Income before income taxes and minority interest			209,221		24,230		104,248		302,282		(321,137)		318,844
	Income tax expense (benefit)		17,545		23,911		(12,465)		110,889		(13,619)		126,262
Income (loss) before minority interest			191,676		319		116,713		191,392		(307,518)		192,582
Minority interest			–		–		–		–		906		906
Net income (loss)		$	191,676	$	319	$	116,713	$	191,392	$	(308,424)	$	191,676

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

				At June 30, 2005
						Guarantor Subsidiaries
										Non-Guarantor		Combining		Combined
				FMC-AG		D-GmbH		FMCH		Subsidiaries		Adjustment		Total
Current assets:
	Cash and cash equivalents			$	1	$	47	$	–	$	57,321	$	–	$	57,369
	Trade accounts receivable, less allowance for doubtful accounts				–		112,941		–		1,339,867		–		1,452,808
	Accounts receivable from related parties				624,189		330,732		214,837		1,783,846		(2,900,446)		53,158
	Inventories				–		127,126		–		386,045		(58,559)		454,612
	Prepaid expenses and other current assets				2,427		19,192		66		215,249		906		237,840
	Deferred taxes				–		–		–		169,086		17,367		186,453
			Total current assets		626,617		590,038		214,903		3,951,414		(2,940,732)		2,442,240
Property, plant and equipment, net					200		85,198		–		1,085,550		(37,493)		1,133,455
Intangible assets					237		16,459		–		577,892		–		594,588
Goodwill					–		3,308		–		3,433,943		–		3,437,251
Deferred taxes					–		–		–		70,549		(43,895)		26,654
Other assets					4,988,366		833,327		3,680,734		(832,751)		(8,496,605)		173,071
	Total assets			$	5,615,420	$	1,528,330	$	3,895,637	$	8,286,597	$	(11,518,725)	$	7,807,259
Current liabilities:
	Accounts payable			$	627	$	21,328	$		$	148,080	$	–	$	170,035
	Accounts payable to related parties				1,589,448		164,785		862,321		1,148,500		(3,645,550)		119,504
	Accrued expenses and other current liabilities				5,503		93,910		911		668,018		4,855		773,197
	Short-term borrowings				35		–		–		417,091		–		417,126
	Short-term borrowings from related parties				–		1,802		–		40,882		–		42,684
	Current portion of long-term debt and capital lease obligations				683		1,948		75,000		177,898		–		255,529
	Income tax payable				112,179		804		–		60,383		648		174,014
	Deferred taxes				1,125		5,002		–		35,820		(27,219)		14,728
		Total current liabilities			1,709,600		289,579		938,232		2,696,672		(3,667,266)		1,966,817
Long term debt and capital lease obligations, less current portion					247,700		605		593,629		407,071		(784,057)		464,948
Long term borrowings from related parties					3,813		185,476		–		(185,477)		(3,812)		–
Other liabilities					4,365		4,762		–		79,472		12,490		101,089
Pension liabilities					1,009		57,598		–		49,155		(8,653)		99,109
Deferred taxes					348		2,295		–		279,373		18,385		300,401
Company obligated mandatorily redeemable preferred securities of subsidiary Fresenius Medical Care Capital Trusts holding solely Company guaranteed debentures of subsidiary					–		–		–		1,208,004		–		1,208,004
Minority interest					–		–		7,412		–		10,894		18,306
		Total liabilities			1,966,835		540,315		1,539,273		4,534,270		(4,422,019)		4,158,674
Shareholders’ equity:					3,648,585		988,015		2,356,364		3,752,327		(7,096,706)		3,648,585
	Total liabilities and shareholders’ equity			$	5,615,420	$	1,528,330	$	3,895,637	$	8,286,597	$	(11,518,725)	$	7,807,259

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

			At December 31, 2004
					Guarantor Subsidiaries
									Non-Guarantor		Combining			Combined
			FMC-AG		D-GmbH		FMCH		Subsidiaries		Adjustment			Total
Current assets:
	Cash and cash equivalents		$	2,152	$	35	$	–	$	56,779	$	–		$	58,966
	Trade accounts receivable, less allowance for doubtful accounts			–		110,204		–		1,353,422		(779	)		1,462,847
	Accounts receivable from related parties			763,089		325,731		213,337		1,792,810		(3,043,207	)		51,760
	Inventories			–		125,952		–		374,560		(57,593	)		442,919
	Prepaid expenses and other current assets			7,347		12,254		22		224,071		399			244,093
	Deferred taxes			–		–		–		166,970		18,415			185,385
		Total current assets		772,588		574,176		213,359		3,968,612		(3,082,765	)		2,445,970
Property, plant and equipment, net				227		100,496		–		1,121,290		(40,086	)		1,181,927
Intangible assets				333		16,384		–		585,331		–			602,048
Goodwill				–		3,726		–		3,441,426		–			3,445,152
Deferred taxes				–				–		32,613		25,510			58,123
Other assets				4,990,303		925,105		3,520,453		522,915		(9,730,455	)		228,321
	Total assets		$	5,763,451	$	1,619,887	$	3,733,812	$	9,672,187	$	(12,827,796	)	$	7,961,541
Current liabilities:
	Accounts payable		$	205	$	16,374	$	–	$	175,973	$	–		$	192,552
	Accounts payable to related parties			1,682,729		359,869		842,204		1,290,323		(4,061,681	)		113,444
	Accrued expenses and other current liabilities			15,800		79,530		541		652,379		(7,175	)		741,075
	Short-term borrowings			38		–		–		419,110		–			419,148
	Short-term borrowings from related parties			–		–		–		5,766		–			5,766
	Current portion of long-term debt and capital lease obligations			770		1,145		25,000		203,264		–			230,179
	Income tax payable			127,331		–		–		102,551		648			230,530
	Deferred taxes			990		4,178		–		35,962		(35,971	)		5,159
		Total current liabilities		1,827,863		461,096		867,745		2,885,328		(4,104,179	)		1,937,853
Long term debt and capital lease obligations, less current portion				248,427		–		650,029		507,847		(860,733	)		545,570
Long term borrowings from related parties				4,295		–		–		–		(4,295	)		–
Other liabilities				41,111		5,834		–		93,839		15,338			156,122
Pension liabilities				1,049		60,084		–		58,333		(11,341	)		108,125
Deferred taxes				5,890		2,376		–		239,162		34,833			282,261
Company obligated mandatorily redeemable preferred securities of subsidiary Fresenius Medical Care Capital Trusts holding solely Company guaranteed debentures of subsidiaries				–		–		–		1,278,760		–			1,278,760
Minority interest				–		–		7,412		–		10,622			18,034
		Total liabilities		2,128,635		529,390		1,525,186		5,063,269		(4,919,755	)		4,326,725
Shareholders’ equity:				3,634,816		1,090,497		2,208,626		4,608,918		(7,908,041	)		3,634,816
	Total liabilities and shareholders’ equity		$	5,763,451	$	1,619,887	$	3,733,812	$	9,672,187	$	(12,827,796	)	$	7,961,541

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

				For the Six Months Period Ended June 30, 2005
							Guarantor
							Subsidiaries
													Non-Guarantor			Combining			Combined
				FMC-AG			D-GmbH			FMCH			Subsidiaries			Adjustment			Total
Operating Activities:
	Net income (loss)			$	223,475		$	2,758		$	132,869		$	266,942		$	(402,569	)	$	223,475
	Adjustments to reconcile net income to cash and cash equivalents provided by (used in) operating activities:
	Equity affiliate income				(177,183	)		–			(148,325	)		–			325,508			–
		Depreciation and amortization			975			14,733			–			113,081			(7,461	)		121,328
		Change in deferred taxes, net			(4,943	)		1,571			–			13,035			10,883			20,546
		(Gain) loss on sale of fixed assets			–			(224	)		–			816			–			592
		Compensation expense related to stock options			832			–			–			–			–			832
		Cash (outflow) inflow from hedging			–			(460	)		–			460			–			–
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			–			(16,052	)		–			(25,509	)		–			(41,561	)
		Inventories			–			(16,271	)		–			(18,884	)		5,412			(29,743	)
		Prepaid expenses and other current and non-current assets			12,334			(3,954	)		1,779			(90,760	)		54,097			(26,504	)
		Accounts receivable from/payable to related parties			(39,473	)		(10,949	)		18,618			39,883			(5,740	)		2,339
		Accounts payable, accrued expenses and other current and non-current liabilities			(1,035	)		36,034			370			(7,507	)		8,797			36,659
		Income tax payable			(912	)		854			(10,304	)		(29,481	)		–			(39,843	)
			Net cash provided by (used in) operating activities		14,070			8,040			(4,993	)		262,076			(11,073	)		268,120
Investing Activities:
	Purchases of property, plant and equipment				(53	)		(9,562	)		–			(102,923	)		7,961			(104,577	)
	Proceeds from sale of property, plant and equipment				–			871			–			6,256			–			7,127
	Disbursement of loans to related parties				89,912			64			11,653			–			(101,629	)		–
	Acquisitions and investments, net of cash acquired				(15,727	)		–			–			(51,636	)		15,649			(51,714	)
			Net cash provided by (used in) investing activities		74,132			(8,627	)		11,653			(148,303	)		(78,019	)		(149,164	)
Financing Activities:
	Short-term borrowings, net				39,575			1,413			–			(28,373	)		–			12,615
	Long-term debt and capital lease obligations, net				(361	)		(809	)		(6,400	)		(121,851	)		101,629			(27,792	)
	Increase of accounts receivable securitization program				–			–			–			27,235			–			27,235
	Proceeds from exercise of stock options				8,042			–			–			–			–			8,042
	Dividends paid				(137,487	)		–			–			(1,504	)		1,504			(137,487	)
	Capital Increase of Non-Guarantor-Subsidiaries				–			–			–			15,650			(15,650	)		–
	Change in minority interest				–			–			(260	)		–			1,169			909
			Net cash (used in) provided by financing activities		(90,231	)		604			(6,660	)		(108,843	)		88,652			(116,478	)
Effect of exchange rate changes on cash and cash equivalents					(122	)		(2	)		–			(4,391	)		440			(4,075	)
Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents					(2,151	)		15			–			539			–			(1,597	)
Cash and cash equivalents at beginning of period					2,152			32			–			56,782			–			58,966
Cash and cash equivalents at end of period				$	1		$	47		$	–		$	57,321		$	–		$	57,369

FRESENIUS MEDICAL CARE AG

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

(Unaudited)

(in thousands, except share and per share data)

				For the Six Months Period Ended June 30, 2004
						Guarantor Subsidiaries
										Non-Guarantor		Combining		Combined
				FMC-AG		D-GmbH		FMCH		Subsidiaries		Adjustment		Total
Operating Activities:
	Net income (loss)			$	191,676	$	319	$	116,713	$	191,392	$	(308,424)	$	191,676
	Adjustments to reconcile net income to cash and cash equivalents provided by (used in) operating activities:
	Equity affiliate income				(138,993)		–		(135,410)		–		274,403		–
		Depreciation and amortization			963		12,753		–		105,823		(5,712)		113,827
		Change in deferred taxes, net			(1,013)		(1,604)		–		5,745		12,901		16,029
		(Gain) loss on sale of fixed assets			–		(402)		–		591		–		189
		Compensation expense related to stock options			802		–		–		–		–		802
		Cash Inflow from hedging			–		–		–		4,422		–		4,422
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			–		(6,793)		–		5,549		–		(1,244)
		Inventories			–		(4,277)		–		(3,769)		1,618		(6,428)
		Prepaid expenses and other current and non-current assets			(6,201)		2,284		1,300		39,657		519		37,559
		Accounts receivable from/payable to related parties			(2,913)		1,809		18,618		(46,461)		10,954		(17,993)
		Accounts payable, accrued expenses and other current and non-current liabilities			808		9,686		(1,692)		(208)		453		9,047
		Income tax payable			(6,229)		–		(12,465)		21,680		–		2,986
			Net cash provided by (used in) operating activities		38,900		13,775		(12,937)		324,422		(13,288)		350,872
Investing Activities:
	Purchases of property, plant and equipment				(153)		(14,229)		–		(93,125)		6,748		(100,759)
	Proceeds from sale of property, plant and equipment				–		873		–		5,107		–		5,980
	Disbursement of loans to related parties				109,390		–		93,997		(623,756)		420,369		–
	Acquisitions and investments, net of cash acquired				(33,379)		–		–		(51,414)		32,847		(51,946)
			Net cash provided by (used in) investing activities		75,858		(13,356)		93,997		(763,188)		459,964		(146,725)
Financing Activities:
	Short-term borrowings, net				(22)		–		–		(33,422)		–		(33,444)
	Long-term debt and capital lease obligations, net				3,667		(660)		(80,800)		403,976		(420,369)		(94,186)
	Decrease of accounts receivable securitization program				–		–		–		68,002		–		68,002
	Proceeds from exercise of stock options				1,067		–		–		–		–		1,067
	Dividends paid				(122,106)		–		–		(5,397)		5,397		(122,106)
	Redemption of Series D Trust Preferred Stock of subsidiary				–		–		–		–		–		–
	Capital Increase of Non-Guarantor- Subsidiaries				–		–		–		32,849		(32,849)		–
	Change in minority interest				–		–		(260)		(759)		906		(113)
			Net cash (used in) provided by financing activities		(117,393)		(660)		(81,060)		465,248		(446,915)		(180,780)
Effect of exchange rate changes on cash and cash equivalents					2,634		(7)		–		(10,136)		239		(7,270)
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					(2)		(248)		–		16,346		–		16,097
Cash and cash equivalents at beginning of period					3		300		–		48,124		–		48,427
Cash and cash equivalents at end of period				$	1	$	52	$	–	$	64,470	$	–	$	64,524

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004

The Company

We have announced that we intend to change our current legal form as an Aktiengesellschaft (“AG”) to a KGaA, which is a German partnership limited by shares (the “Transformation of Legal Form”). As a KGaA, we will be the same legal entity under German law, rather than a successor to the AG. Fresenius Medical Care Management AG, a subsidiary of Fresenius AG, the ultimate parent of FMC-AG, will be the general partner of the Company. The transformation of legal form is subject to approval by our ordinary shareholders which will be voted upon by the ordinary shareholders at the Extraordinary General Meeting (“EGM”) to be held on August 30, 2005.

We also announced that we intend to offer our preference shareholders the opportunity to convert their preference shares into ordinary shares on a one-to-one basis pursuant to a conversion offer to be conducted after the EGM. Preference shareholders who decide to convert their shares will be required to pay a premium and will lose their preferential dividend rights. The conversion is subject to approval of the ordinary shareholders at the EGM and also subject to approval by a separate vote of our preference shareholders which will be voted upon at a separate meeting of the preference shareholders immediately following the EGM on August 30, 2005 or, if necessary, on August 31, 2005.

You should read the following discussion and analysis of the results of our operations in conjunction with our unaudited consolidated financial statements and related notes contained elsewhere in this report. Some of the statements contained below, including those concerning future revenue, costs and capital expenditures and possible changes in our industry and competitive and financial conditions include forward-looking statements. Because such statements involve risks and uncertainties, actual results may differ materially from the results which the forward looking statements express or imply.

Financial Condition and Results of Operations

This report contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are based upon our current expectations, assumptions, estimates and projections about us and our industry that address, among other things:

• our business development, operating development and financial condition; • our expectations of growth in the patient population regarding renal dialysis products and services; • our ability to remain competitive in the markets for our products and services; • the effects of regulatory developments, legal and tax proceedings and any resolution of government investigations into our business; • changes in government reimbursement policies and those of private payors; • changes in pharmaceutical administration patterns or reimbursement policies; • our ability to develop and maintain additional sources of financing; and

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

• other statements of our expectations, beliefs, future plans and strategies, anticipated development and other matters that are not historical facts.

When used in this report, the words “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions are generally intended to identify forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, financial and otherwise, could differ materially from those set forth in or contemplated by the forward-looking statements contained in this report. Important factors that could contribute to such differences are noted in the risk factors section of our Annual Report on Form 20-F, and in this report in Part I, Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations and Part II, Item 1, Legal Proceedings. These risks and uncertainties include: general economic, currency exchange and other market conditions, litigation and regulatory compliance risks, changes in government reimbursement for our dialysis care and pharmaceuticals, the investigations by the Department of Justice, Eastern District of New York, and the Department of Justice, Eastern District of Missouri, and changes to pharmaceutical utilization patterns.

This report should be read in conjunction with our disclosures and discussions contained in our Annual Report on Form 20-F for the year ended December 31, 2004.

Our business is also subject to other risks and uncertainties that we describe from time to time in our public filings. Developments in any of these areas could cause our results to differ materially from the results that we or others have projected or may project.

Overview

We are engaged primarily in providing dialysis services and manufacturing and distributing products and equipment for the treatment of end-stage renal disease. In the United States, we also perform clinical laboratory testing and provide perfusion autotransfusion, and therapeutic apheresis services. Perfusion maintains human heart and lung function during cardiovascular surgery. Autotransfusion is used during surgery to collect, filter and reinfuse a patient’s own blood as an alternative to using donor blood. Therapeutic apheresis is the process of separating or removing illness-causing substances from patient’s blood or blood plasma. Dialysis is a lifesaving treatment for irreversible, lifelong end stage renal disease, and necessitates multiple treatments per week for the remainder of a patient’s life. We estimate that providing dialysis services and the distribution of dialysis products and equipment represents an over $40 billion worldwide market with expected annual patient growth of 6%. Patient growth results from factors such as the aging population; increasing incidence of diabetes and hypertension, which frequently precede the onset of ESRD; improvements in treatment quality, which prolong patient life; and improving standards of living in developing countries, which make life saving dialysis treatment available. Key to continued growth in revenue is our ability to attract new patients in order to increase the number of treatments performed each year. For that reason, we believe the number of treatments performed each year is a strong indicator of continued revenue growth and success. In addition, the reimbursement and ancillary utilization environment significantly influence our business. In the past we experienced and also expect in the future generally stable reimbursement levels for dialysis services. This includes the balancing of unfavorable reimbursement changes in certain countries with favorable changes in other countries. The majority of treatments are paid for by governmental institutions such as Medicare in the United States. As a consequence of the pressure to decrease health care costs, reimbursement rate increases have been limited. Our ability to influence the pricing of our services is limited. Profitability depends on our ability to manage rising labor, drug and supply costs.

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

On December 8, 2003, the Medicare Prescription Drug, Modernization and Improvement Act of 2003 was enacted (the “MMA”). This law made several significant changes to U.S. government payment for dialysis services and pharmaceuticals. First, it increased the composite rate for renal dialysis facilities by 1.6% on January 1, 2005. Second, effective January 1, 2005, it based the payments for ten separately billable dialysis-related medications on average acquisition cost (as determined by the Office of the Inspector General (“OIG”) and updated by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services (“CMS”), and payments for the remaining separately billable dialysis-related medications will be based on average sales price (“ASP”) plus 6% (ASP is defined in the law as a manufacturer’s ASP to all purchasers in a calendar quarter per unit of each drug and biological sold in that same calendar quarter, excluding sales exempt from best price and nominal price sales and including all discounts, chargebacks and rebates). Third, the difference between the determined acquisition cost-based reimbursement and what would have been received under the current average wholesale price-based (“AWP-based”) reimbursement methodology is added to the composite rate. This add-back amount has been determined to be 8.7% of the composite rate and will be subject to an annual update based on the growth in drug spending. Fourth, effective April 1, 2005, providers receive higher composite rate payments for certain patients based on their age, body mass index and body surface area. Fifth, beginning in 2006, the Secretary of the Department of Health and Human Services (the “Secretary”) is authorized to set payment for all separately billed drugs and biologicals at either acquisition cost or average sales price. Lastly, the Secretary is required to establish a three-year demonstration project to test the use of a fully case-mix adjusted payment system for ESRD services, beginning January 1, 2006. Under this project, separately billable drugs and biologicals and related clinical laboratory tests would be bundled into the facility composite rate. Participating facilities would receive an additional 1.6% composite rate increase. Under the final MMA regulations for 2005, we are experiencing and will continue to experience during 2005 a non-material negative impact, excluding the effects of the 1.6% composite rate increase, on our revenue from Medicare as compared to 2004.

On August 1, 2005, CMS announced proposed rules under MMA for 2006 that would: (i) modify the geographic and wage index adjustments applied to the composite rate, (ii) change the drug payment methodology for all separately billed dialysis-related drugs and biologicals from average acquisition cost pricing to ASP plus 6%, and (iii) increase the composite rate drug add-on adjustment from 8.7% to 8.9%. Comments on the proposed rules will be accepted until September 30, 2005. We are in the process of analyzing the proposed rules and any potential impact they may have on our operating results.

In July 2004, CMS proposed certain changes with respect to its EPO reimbursement and utilization guidelines. Its proposal reflects the agency’s conclusion that the appropriate utilization of EPO should be monitored by considering both the patient’s hemoglobin/hematocrit level and the dosage. Specifically, it proposed a pre-payment claims review process in which claims for EPO with hemoglobin levels below 13 (or hematocrit of 39) would not be targeted for review, but claims for EPO with hemoglobin levels above 13 would be reviewed based on the hemoglobin value and related EPO doses, and with payment limited to a fixed amount of EPO unless there is medical justification for the hemoglobin levels. The comment period on this policy draft ended on October 7, 2004. CMS has not yet finalized the new guidelines. Administration of EPO accounted for approximately 23% of dialysis care revenue in our North America segment in 2004. If the proposed revision to CMS’s EPO reimbursement/utilization guidelines is adopted, this could have an adverse impact on our operating results.

Our operations are organized geographically and accordingly we have identified three operating segments, North America, International, and Asia Pacific. For management purposes, the Company reclassified its Mexico operations from its International segment to its North American segment beginning January 1, 2005 and reclassified the operations and assets for the comparative interim periods of 2004. For reporting purposes,

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

we have aggregated the International and Asia Pacific segments as “International”. We aggregated these segments due to their similar economic characteristics. These characteristics include same services provided and same products sold, same type patient population, similar methods of distribution of products and services and similar economic environments. Our management board members responsible for the profitability and cash flow of each segment’s various businesses supervises the management of each operating segment. The accounting policies of the operating segments are the same as those we apply in preparing our consolidated financial statements under accounting principles generally accepted in the United States (“U.S. GAAP”). Our management evaluates each segment using a measure that reflects all of the segment’s controllable revenues and expenses.

With respect to the performance of our business operations, our management believes the most appropriate measure in this regard is operating income, which measures our source of earnings. Financing is a corporate function which segments do not control. Therefore, we do not include interest expense relating to financing as a segment measurement. We also regard income taxes to be outside the segments’ control.

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

Results of Operations

The following table summarizes our financial performance and certain operating results by principal business segment for the periods indicated. Inter-segment sales primarily reflect sales of medical equipment and supplies from the International segment to the North America segment. We prepared the information using a management approach, consistent with the basis and manner in which our management internally disaggregates financial information to assist in making internal operating decisions and evaluating management performance.

			For the Three Months
			Ended June 30,
			2005		2004
			(Unaudited)
			(In millions)
Total revenue
	North America		$	1,127	$	1,061
	International			561		501
		Totals		1,688		1,562
Inter-segment revenue
	North America			–		1
	International			14		9
		Totals		14		10
Total net revenue
	North America			1,127		1,060
	International			547		492
		Totals		1,674		1,552
Amortization and depreciation
	North America			35		32
	International			26		25
	Corporate			–		–
		Totals		61		57
Operating income (EBIT)
	North America			157		147
	International			92		75
	Corporate			(11)		(9)
		Totals		238		213
Interest income				4		3
Interest expense				(47)		(48)
Income tax expense				(79)		(67)
Minority interest				–		–
Net income			$	116	$	101

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

			For the Six Months
			Ended June 30,
			2005		2004
			(Unaudited)
			(In millions)
Total revenue
	North America		$	2,216	$	2,064
	International			1,094		966
		Totals		3,310		3,030
Inter-segment revenue
	North America			1		1
	International			26		18
		Totals		27		19
Total net revenue
	North America			2,215		2,063
	International			1,068		948
		Totals		3,283		3,011
Amortization and depreciation
	North America			69		64
	International			52		49
	Corporate			–		1
		Totals		121		114
Operating income (EBIT)
	North America			304		283
	International			174		146
	Corporate			(20)		(18)
		Totals		458		411
Interest income				6		6
Interest expense				(91)		(98)
Income tax expense				(149)		(126)
Minority interest				(1)		(1)
Net income			$	223	$	192

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

Three months ended June 30, 2005 compared to three months ended June 30, 2004

Key Indicators for Consolidated Financial Statements
							Change in %
	Three Months			Three Months
	Ended			Ended					At Constant
	June 30, 2005			June 30, 2004			As Reported		Exchange Rates
Number of treatments		4,884,892			4,672,151			5%
Same store treatment growth in %		4.7	%		3.8	%
Revenue in $ million		1,674			1,552			8%		6%
Gross profit in % of revenue		35.1	%		33.8	%
Selling, general and administrative costs in % of revenue		20.1	%		19.2	%
Net income in $ million		116			101			15%

Net revenue increased for the quarter ended June 30, 2005 over the comparable period in 2004 due to growth in revenue in both dialysis care and dialysis products.

Dialysis care revenue grew by 6% to $1,201 million (6% at constant exchange rates) in the second quarter of 2005 mainly due to the growth in same store treatments combined with increased revenue per treatment. Dialysis product revenue increased by 11% to $473 million (7% at constant exchange rates) in the same period.

The increase in gross profit margin is primarily a result of higher revenue rates in North America and growth in regions which have higher gross margins partially offset by higher personnel expenses in North America. Depreciation and amortization expense for the second quarter of 2005 was $61 million compared to $57 million for the same period in 2004.

Selling, general and administrative costs increased from $298 million in the second quarter of 2004 to $336 million in the same period of 2005. Selling, general and administrative costs as a percentage of sales increased from 19.2% in the second quarter of 2004 to 20.1% in the same period of 2005. The percentage increase is mainly due to higher insurance costs, increased delivery costs due to higher fuel prices and higher commercial delivery costs in North America as well as restructuring costs in Japan partially offset by foreign currency gains in the International segment and lower personnel expenses in North America.

Bad debt expense for the second quarter 2005 was $35 million compared to $32 million for 2004 with both amounts representing 2.1% of sales in their respective three-month periods.

Net income for the period was $116 million compared to $101 million in the second quarter of 2004.

The number of treatments in the second quarter of 2005 represents an increase of 5% over the same period in 2004, mostly as a result of same store treatment growth.

At June 30, 2005 we owned, operated or managed 1,645 clinics compared to 1,595 clinics at June 30, 2004. During the second quarter of 2005, we acquired 10 clinics, opened 14 clinics and closed or sold 12 clinics. The number of patients treated in clinics that we own, operate or manage increased from approximately 122,800 at June 30, 2004 to approximately 128,200 at June 30, 2005. Average revenue per treatment for world-wide dialysis services increased 2% from $241 to $246 mainly due to worldwide improved revenue rate per treatment and favorable currency developments.

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

The following discussions pertain to our business segments and the measures we use to manage these segments.

North America Segment

Key Indicators for North America Segment
	Three Months			Three Months
	Ended			Ended
	June 30, 2005			June 30, 2004			Change in %
Number of treatments		3,355,159			3,228,405			4	%
Same store treatment growth in %		3.6	%		3.6	%
Revenue in $ million		1,127			1,060			6	%
Depreciation and amortization in $ million		35			32			7	%
Operating income in $ million		157			147			7	%
Operating income margin in %		14.0	%		13.9	%

Revenue

Net revenue for the North America segment for the second quarter 2005 increased as a result of increases in dialysis care revenue by 5% from $950 million to $1,000 million and product sales revenue by 15% from $110 million to $127 million.

The dialysis care revenue increased by 5% driven by the approximate 4% increase in same store treatment growth, acquisitions of approximately 1%, revenue per treatment increase of approximately 1% and offset by approximately 1% as a result of closed or sold clinics. The administration of EPO represented approximately 24% and 26% of total North America dialysis care revenue for the periods ending June 30, 2005 and 2004, respectively.

At June 30, 2005, approximately 88,600 patients were being treated in the 1,150 clinics that we own, operate or manage in the North America segment, compared to approximately 85,500 patients treated in 1,135 clinics at June 30, 2004. The average revenue per treatment, excluding laboratory testing revenue, increased from $277 in 2004 to $281 in 2005. Including laboratory testing, the average revenue per treatment in the second quarter increased from $287 in 2004 to $292 during 2005. In the U.S., average revenue per treatment including laboratory testing increased from $289 in the second quarter of 2004 to $294 in the same period in 2005. The improvement in the revenue rate per treatment is primarily due to increases in the dialysis treatment reimbursement rates including the 1.6% legislated increase from Medicare and the transfer of Medicare drug reimbursements for separately billable items into the composite rate (see Overview above).

Operating Income

Operating income increased by 7% from $147 million for the period ended June 30, 2004 to $157 million for the same period in 2005 primarily due to increased treatments and a higher volume of products sold. Operating margin increased from 13.9% for the second period in 2004 as compared to 14.0% for the same period in 2005. Operating margin increased mostly as a result of improvement in revenue rates partially offset by higher personnel expenses, increased bad debt expense, increased insurance costs and increased delivery costs due to higher fuel prices and higher commercial delivery costs. Cost per treatment increased from $251 in 2004 to $253 in 2005.

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

International Segment

Key Indicators for International Segment
							Change in %
	Three Months			Three Months
	Ended			Ended					At Constant
	June 30, 2005			June 30, 2004			As Reported		Exchange Rates
Number of treatments		1,529,733			1,443,746			6%
Same store treatment growth in %		7.1	%		4.2	%
Revenue in $ million		547			492			11%		6%
Depreciation and amortization in $ million		26			24			9%
Operating income in $ million		92			75			23%
Operating income margin in %		16.8	%		15.2	%

Revenue

The 11% increase in net revenues for the International segment resulted from increases in both dialysis care and dialysis product revenues. Organic growth during the period of approximately 7% at constant exchange rates was slightly offset due to the impact of closed or sold clinics. This increase was also attributable to a 5% exchange rate effect due to the continued strengthening of various local currencies against the US dollar in 2004 and 2005.

Including the effects of the acquisitions, European region revenue increased 10% (6% at constant exchange rates), Latin America region revenue increased 20% (10% at constant exchange rates), and Asia Pacific region revenue increased 8% (3% at constant exchange rates).

Total dialysis care revenue for the entire International segment increased during the second quarter of 2005 by 13% (7% at constant exchange rates) to $200 million in 2005 from $177 million in the same period of 2004. This increase is a result of organic growth of 12% partially offset by a 5% decrease as a result of the impact of closed or sold clinics and increased by approximately 6% due to exchange rate fluctuations.

As of June 30, 2005, approximately 39,600 patients were being treated at 495 clinics that we own, operate or manage in the International segment compared to 37,300 patients treated at 460 clinics at June 30, 2004. The average revenue per treatment increased from $123 to $131 ($124 at constant exchange rates) due to the strengthening of the local currencies against the US dollar and increased reimbursement rates partially offset by growth in countries with reimbursement rates below the average.

Total dialysis product revenue for the second quarter of 2005 increased by 10% (5% at constant exchange rates) to $346 million.

Operating Income

Our operating income increased by 23% to $92 million primarily as a result of an increase in treatment volume and in volume of products sold. Operating margin increased from 15.2% to 16.8%. The main causes for the margin increase were foreign currency gains, a reimbursement rate increase in Turkey, lower bad debt expense, and lower depreciation as a percentage of revenue partially offset by restructuring costs in Japan.

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

Corporate

We do not allocate “corporate costs” to our segments in calculating segment operating income as we believe that these costs are not within the control of the individual segments. These corporate costs primarily relate to certain headquarters overhead charges including accounting and finance, professional services, etc.

Total corporate operating loss was $11 million in the quarter ended June 30, 2005 compared to an operating loss of $9 million in the same period of 2004.

The following discussions pertain to our total Company costs.

Interest

Interest expense for the second quarter of 2005 decreased 4% to $47 million as compared to $48 million in the same period in 2004 due to lower debt levels resulting from the use of positive cash flows and lower interest rates as a result of amendments to the 2003 Senior Credit Agreement.

Income Taxes

The effective tax rate for the quarter ended June 30, 2005 was 40.4% compared to 39.8% during the same period in 2004.

Six months ended June 30, 2005 compared to six months ended June 30, 2004

Key Indicators for Consolidated Financial Statements
							Change in %
	Six Months			Six Months
	Ended			Ended					At Constant
	June 30, 2005			June 30, 2004			As Reported		Exchange Rates
Number of treatments		9,601,674			9,241,639			4%
Same store treatment growth in %		4.6	%		3.9	%
Revenue in $ million		3,283			3,011			9%		7%
Gross profit in % of revenue		34.3	%		33.4	%
Selling, general and administrative costs in % of revenue		19.5	%		18.9	%
Net income in $ million		223			192			17%

Net revenue increased by 9% for the six months ended June 30, 2005 over the comparable period in 2004 due to growth in revenue in both dialysis care and dialysis products.

Dialysis care revenue grew by 8% to $2,363 million (7% at constant exchange rates) in the first six months of 2005 mainly due to higher revenue rates, acquisitions, and as result of an accounting change for the implementation of Financial Accounting Standards Board Interpretation No. 46R (“FIN 46R”), issued December 2003 and effective March 31, 2004), partially offset by the effect of one less treatment day in North America in the first quarter of 2005. Dialysis product revenue increased by 11% to $920 million (7% at constant exchange rates) in the same period.

Gross profit margin improved to 34.3% in the six months ended June 30, 2005 from 33.4% for 2004. The increase is primarily a result of higher revenue rates and growth in regions which have higher gross margins partially offset by higher personnel expenses, and one less treatment day in North America. Depreciation and

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

amortization expense for the period ended June 30, 2005 was $121 million compared to $114 million for the same period in 2004.

Selling, general and administrative costs increased from $570 million in the first six months of 2004 to $642 million in the same period of 2005. Selling, general and administrative costs as a percentage of sales increased from 18.9% in the six months ended June 30, 2004 to 19.5% in the same period of 2005. The increase is mainly due to higher insurance costs, foreign exchange losses, and higher delivery costs due to higher fuel prices and higher commercial delivery costs in North America, as well as restructuring costs in Japan. This increase was partially offset by lower bad debt expense in the International segment as a percentage of sales, the one time impact of compensation for cancellation of a distribution contract in Japan and a patent litigation settlement as well as foreign currency gains in the International segment. Net income for the period was $223 million compared to $192 million in 2004.

Bad debt expense for the first six months in 2005 was $65 million representing 2.0% of revenues compared to $63 million representing 2.1% of revenues for the same period in 2004.

In the six months ended June 30, 2005, we provided 9.6 million treatments. This represents an increase of 4% over the same period in 2004. Same store treatment growth was approximately 5% with additional growth of 1% from acquisitions reduced by approximately 1% due to closed or sold clinics and by 1% due to the effects of one less dialysis day in North America. During the first six months of 2005, we acquired 20 clinics, opened 37 clinics and closed or sold 20 clinics. Average revenue per treatment for world-wide dialysis services increased from $236 to $246 mainly due to worldwide improved reimbursement rates and favorable currency developments.

The following discussions pertain to our business segments and the measures we use to manage these segments.

North America Segment

Key Indicators for North America Segment
	Six Months			Six Months
	Ended June 30,			Ended June 30,
	2005			2004			Change in %
Number of treatments		6,605,269			6,398,493			3	%
Same store treatment growth in %		3.7	%		3.2	%
Revenue in $ million		2,215			2,063			7	%
Depreciation and amortization in $ million		69			64			7	%
Operating income in $ million		304			283			7	%
Operating income margin in %		13.7	%		13.7	%

Revenue

Net revenue for the North America segment for the first six months of 2005 increased by 7% because dialysis care revenue increased by 6% from $1,849 million to $1,969 million and products sales increased by 15% to 246 million.

The 6% increase in dialysis care revenue in the six-month period ending June 30, 2005, was driven by approximately 3% increase in treatments, revenue rate per treatment increase of approximately 2% and approximately 1% resulting from an accounting change (implementation of FIN 46R). The 3% increase in treatments was the result of same store treatment growth of 4% and 1% increase resulting from acquisitions

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

offset by approximately 1% decrease attributable to one less treatment day and 1% decrease due to closed or sold clinics. For the first six months of 2005, the administration of EPO represented approximately 24% of total North America revenue as compared to 26% in the prior year.

The average revenue per treatment, excluding laboratory testing revenue, increased from $275 in 2004 to $280 in 2005. Including laboratory testing the average revenue per treatment in the first six months increased from $286 in 2004 to $291 during 2005. In the U.S., average revenue per treatment including laboratory testing increased from $287 for the first half of 2004 to $293 in the first half of 2005.

Operating income

Operating income increased by 7% from $283 million for the first half of 2004 to $304 million due to increased treatments and a higher volume of products sold. Operating margin remained at the same level for the first six months of 2005 as compared to the same period in 2004 mostly as a result of improvement in revenue rates offset by higher personnel costs, higher insurance costs, increased bad debt expense, higher facility costs, foreign exchange losses, one less dialysis day in the first quarter of 2005, and higher delivery costs due to higher fuel prices and higher commercial delivery costs. Cost per treatment increased from $250 in 2004 to $253 in 2005.

International Segment

Key Indicators for International Segment
							Change in %
	Six Months			Six Months
	Ended			Ended						At Constant
	June 30, 2005			June 30, 2004			As Reported			Exchange Rates
Number of treatments		2,996,405			2,843,146			5	%
Same store treatment growth in %		6.5	%		5.5	%
Revenue in $ million		1,068			948			13	%		7	%
Depreciation and amortization in $ million		52			49			6	%
Operating income in $ million		174			146			19	%
Operating income margin in %		16.3	%		15.4	%

Revenue

The 13% increase in net revenues for the International segment resulted from increases in both dialysis care and dialysis product revenues. Organic growth during the period was 6% at constant exchange rates. Acquisitions and the impact of consolidations resulting from implementation of FIN 46R contributed approximately 1%. This increase was also attributable to a 6% exchange rate effect due to the continued strengthening of various local currencies against the dollar.

Total dialysis care revenue increased during the first six months of 2005 by 17% (11% at constant exchange rates) to $394 million in 2005 from $336 million in the same period of 2004. This increase is a result of organic growth of 10%, 1% increase in contributions from acquisitions, 3% contributions from consolidations resulting from an accounting change (implementation of FIN 46R) partially offset by a decrease of 3% due to closed or sold stores and increased by approximately 6% due to exchange rate fluctuations.

In the first six months of 2005, the average revenue per treatment increased from $118 to $132 ($125 at constant exchange rates) due to the strengthening of the local currencies against the U.S. dollar and increased

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

reimbursement rates partially offset by growth in countries with reimbursement rates below the average and by the effect of the loss of tenders and the breach of a contract.

Total dialysis product revenue for the first six months of 2005 increased by 10% (5% at constant exchange rates) to $673 million.

Including the effects of the acquisitions, European region revenue increased 13% (7% at constant exchange rates), Latin America region revenue increased 28% (19% at constant exchange rates), and Asia Pacific region revenue increased 3% (2% decrease at constant exchange rates).

Operating income

Our operating income increased from $146 million in the first half of 2004 to $174 million for the same period in 2005. The operating margin increased from 15.4% in the first six months of 2004 to 16.3% for the same period in 2005. The main causes for the margin increase were foreign currency gains, lower depreciation as a percentage of revenue, reimbursement rate increases in Turkey, lower bad debt expense and the one time effects of income associated with the cancellation of a distribution agreement and settlement of a patent litigation partially offset by restructuring costs in Japan, foreign currency losses of non-hedged accounts receivables, and a reimbursement rate reduction in Taiwan.

Corporate

Total corporate operating loss was $20 million in the six months ended June 30, 2005 compared to $18 million in the same period of 2004.

The following discussions pertain to our total Company costs.

Interest

Interest expense for the first six months of 2005 decreased 7% to $91 million from $98 million in the same period in 2004 due to a lower debt level resulting from the use of positive cash flows and lower interest rates as a result of amendments to the 2003 Senior Credit Agreement.

Income Taxes

The effective tax rate for the six months ended June 30, 2005 was 39.8% compared to 39.6% during the same period in 2004.

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

LIQUIDITY AND CAPITAL RESOURCES

Six months ended June 30, 2005 compared to six months ended June 30, 2004

Cash Flow

Liquidity

Our primary sources of liquidity have historically been cash from operations, cash from short-term borrowings as well as from long-term debt from third parties and from related parties and cash from issuance of Preference shares and trust preferred securities. Cash from operations is impacted by the profitability of our business and the development of our working capital, principally receivables. The profitability of our business depends significantly on reimbursement rates. Approximately 72% of our revenues are generated from providing dialysis treatment, a major portion of which is reimbursed by either public health care organizations or private insurers. For the six months ended June 30, 2005, approximately 37% of our consolidated revenues resulted from U.S. federal health care benefit programs, such as Medicare and Medicaid reimbursement. Legislative changes could affect all Medicare reimbursement rates for the services we provide, as well as the scope of Medicare coverage. A decrease in reimbursement rates could have a material adverse effect on our business, financial condition and results of operations and thus on our capacity to generate cash flow. See “Overview”, above, for a discussion of recent Medicare reimbursement rate changes. Cash from operations also depends on the collection of accounts receivable. We could face difficulties in enforcing and collecting accounts receivable under some countries’ legal systems. Some customers and governments may have longer payment cycles. This could have a material adverse effect on our capacity to generate cash flow.

The accounts receivable balance at June 30, 2005 and December 31, 2004, net of valuation allowances, represented approximately 83 and 84 days of net revenue, respectively. The development of days sales outstanding by operating segment is shown in the table below;

Development of Days Sales Outstanding
		June 30, 2005		December 31, 2004
North America			65		67
International			123		119
	Total		83		84

Cash from short-term borrowings can be generated by selling interests in accounts receivable (accounts receivable facility) and by borrowing from our parent, Fresenius AG. Long-term financing is provided by the revolving portion and term loans under our 2003 Senior Credit Agreement and has been provided through the issuance of our Euro Notes and trust preferred securities. We believe that our existing credit facilities, cash generated from operations, other current sources of financing and our ability to access capital markets are sufficient to meet our foreseeable needs (See “Outlook – Proposed Acquisition”).

At June 30, 2005, we had approximately $80 million of letters of credit outstanding and approximately $641 million of borrowing capacity available under the revolving portion of our 2003 Senior Credit Agreement.

Our amended 2003 Senior Credit Agreement and the indentures relating to our trust preferred securities include covenants that require us to maintain certain financial ratios or meet other financial tests. Under our 2003 Senior Credit Agreement, we are obligated to maintain a minimum consolidated net worth, a minimum consolidated interest coverage ratio (ratio of consolidated EBITDA to consolidated net interest expense as defined in the 2003 Senior Credit Agreement) and a maximum consolidated leverage ratio (ratio of consolidated funded debt to consolidated EBITDA as defined in the 2003 Senior Credit Agreement).

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

Our amended 2003 Senior Credit Agreement and our indentures include other covenants which, among other things, restrict or have the effect of restricting our ability to dispose of assets, incur debt, pay dividends (limited to $200 million in 2006, dividends paid in 2005 were $137 million) and other restricted payments, create liens or make capital expenditures, investments or acquisitions. The breach of any of the covenants could result in a default under the 2003 Senior Credit Agreement or the notes underlying our trust preferred securities, which could, in turn, create additional defaults under the agreements relating to our other long-term indebtedness. In default, the outstanding balance under the amended 2003 Senior Credit Agreement becomes due at the option of the Lenders thereunder. As of June 30, 2005, we are in compliance with all financial covenants under the 2003 Senior Credit Agreement.

We have an accounts receivable facility whereby certain receivables are sold to NMC Funding, a special purpose entity and a wholly-owned subsidiary. NMC Funding then sells and assigns undivided ownership interests in the accounts receivable to certain bank investors. As we have the right to repurchase the then outstanding interests at any time, the receivables remain on our consolidated balance sheet and the proceeds from the sale of undivided interests are recorded as short-term borrowings. The accounts receivable facility is available through October 20, 2005, and is typically renewed annually; the repurchase of all transferred interests in the accounts receivable would result in the termination of the accounts receivable facility under the terms of the facility agreement.

Our capacity to generate cash from the accounts receivable facility depends on the availability of sufficient accounts receivable that meet certain criteria defined in the agreement with the third party funding corporation. A lack of availability of such accounts receivable could have a material impact on our capacity to utilize the facility for our financial needs.

The settlement agreement with the asbestos creditors committees on behalf of the W.R. Grace & Co. bankruptcy estate (see Part II, Item 1, “Legal Proceedings”) provides for payment by us of $115 million upon approval of the settlement agreement by the U.S. District Court, which has occurred, and confirmation of a W.R. Grace & Co. bankruptcy reorganization plan that includes the settlement. The $115 million obligation is included in the special charge we recorded in 2001 to address 1996 merger-related legal matters.

We are subject to ongoing tax audits in the U.S., Germany and other jurisdictions. We have received notices of unfavorable adjustments and disallowances in connection with certain of the audits. We are contesting, if necessary by way of appeal, certain of these unfavorable determinations. We may be subject to additional unfavorable adjustments and disallowances in connection with ongoing audits. If our objections and any final audit appeals are unsuccessful, we could be required to make additional tax payments. With respect to adjustments and disallowances currently contested, we do not anticipate that an unfavorable ruling would have a material impact on our results of operations. We are not currently able to determine the timing of these potential additional tax payments. If all potential additional tax payments and the Grace Chapter 11 Proceedings settlement payment were to occur contemporaneously, there could be a material adverse impact on our operating cash flow in the relevant reporting period. Nonetheless, we anticipate that cash from operations and, if required, our available liquidity will be sufficient to satisfy all such obligations if and when they come due.

Operations

We generated cash from operating activities of $268 million in the six months ended June 30, 2005 and $351 million in the comparable period in 2004, a decrease of about 24% over the prior year. Cash flows were impacted principally by $53 million of higher tax payments in 2005, an increase in inventory and by a

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

reduction of one days sales outstanding in the first six months of 2005 versus a reduction of three days in the first 6 months of 2004.

Investing

Cash used in investing activities increased slightly from $147 million to $149. In the first six months of 2005, we paid approximately $52 million ($40 million for the North American segment and $12 million for the International segment) cash for acquisitions consisting primarily of dialysis clinics. In the same period in 2004, we also paid approximately $52 million ($36 million for the North American segment and $16 million for the International segment) cash for acquisitions consisting primarily of dialysis clinics.

In addition, capital expenditures for property, plant and equipment net of disposals were $97 million for the six months ended June 30, 2005 and $95 million in 2004. In 2005, capital expenditures were $50 million in the North America segment and $47 million for the International segment. In 2004, capital expenditures were $58 million in the North America segment and $37 million for the International segment. The majority of our capital expenditures were used for the maintenance of existing clinics, equipping new clinics and the expansion of production facilities primarily in France, Italy, Germany and North America. Capital expenditures were approximately 3.0% of total revenue.

Financing

Net cash used in financing was $116 million in the first six months of 2005 compared to cash used in financing of $181 million in the same period of 2004. Dividends in the amount of $137 million relating to 2004 were paid in the first half of 2005 compared to a similar payment of $122 made in the first six months of 2004 for 2003. Our external financing needs decreased due to cash generated from operating activities partially offset by payments for investing activities. Cash on hand was $57 million at June 30, 2005 compared to $65 million at June 30, 2004.

Outlook

Proposed Acquisition

On May 4th, 2005, we entered into a definitive merger agreement for the acquisition of Renal Care Group, Inc. (“RCG”) for an all cash purchase price of approximately $3.5 billion. To finance the proposed acquisition, we have received a commitment for $5.0 billion in senior credit facilities to be underwritten by Bank of America, N.A. (“BofA”) and Deutsche Bank AG New York Branch (“DB”). Loans under the senior credit facilities will be available to us to pay the purchase price and related expenses for the acquisition of RCG, to refinance the outstanding indebtedness under our existing 2003 Senior Credit Agreement and certain indebtedness of RCG, and for general corporate purposes. The senior credit facilities will consist of a 5-year $1.0 billion revolving credit facility, a 5-year $2.0 billion term loan A facility, and a 7-year $2.0 billion term loan B facility. Interest on the senior credit facilities will be at the option of the borrowers at a rate equal to either (i) LIBOR plus an applicable margin, or (ii) the higher of BofA’s prime rate or the Federal Funds rate plus 0.5% plus the applicable margin. The applicable margin is variable and depends on the consolidated leverage ratio of the borrowers.

The senior credit facilities will be guaranteed by FMC-AG and FMCH and certain of their respective subsidiaries and secured by pledges of the stock of certain of our material subsidiaries. The borrowers and guarantors under the senior credit facilities will provide liens on substantially all of their personal property and material real property if the non-credit enhanced senior secured debt rating of the borrowers falls below a certain level and if a grant of security interests is determined appropriate by a cost-benefit analysis. The

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

closing of the senior credit facilities will be subject, among other things, to the negotiation and execution of definitive documents, the non-occurrence of a material adverse effect in relation to RCG, and the refinancing of the indebtedness under our existing Senior Credit Agreement and certain indebtedness of RCG. BofA and DB also must approve any material modification to the merger agreement and any waiver of any material conditions precedent under that agreement. On June 15, 2005, the Company announced it had received a second request from the U.S. Federal Trade Commission (“FTC”) for additional information in connection with this proposed acquisition. The effect of this request, which was anticipated when the acquisition was announced, is to extend the waiting period imposed by the Act until 30 days after the Company and RCG have complied with the request, unless that period is voluntarily extended by the parties or is terminated by the FTC.

In conjunction with the proposed acquisition of Renal Care Group, Inc. and the forecasted variable rate interest payments for its financing, in June and July, 2005, we entered into forward starting interest rate swaps in the notional amount of $1.5 billion. These instruments, designated as cash flow hedges, effectively convert forecasted variable rate interest payments into fixed rate interest payments with an average fixed rate of 4.185% plus an applicable margin. These swaps are denominated in U.S. dollars and expire at various dates in 2010 and 2011. At June 30, 2005, the changes in fair value of these cash flow hedges have been recorded in other comprehensive income.

We believe the proposed acquisition will be consummated in late 2005 and be earnings neutral to slightly accretive in 2006 and accretive from 2007 onward.

Investing

We plan to make acquisitions in the range of $150 to $200 million, including those made to date and excluding the Proposed Acquisition noted above. This is a reduction of approximately $50 million from our original plan of $200 to $250 million during 2005. We still expect to make capital expenditures of $350 to $400 million, including those made to date, in accordance with our original plan.

Net Income

We expect our net income for the year to increase by 12-15% before expected one time cost of $10 million related to the Transformation of Legal Form and the conversion of the preference shares into ordinary shares, up from the original plan of net income increase in the low double digits.

EBITDA

EBITDA (earnings before interest, taxes, depreciation and amortization) was approximately $579 million, 17.7% of sales, for the first six months of 2005 and $525 million, 17.4% of sales, for the first half 2004. EBITDA is the basis for determining compliance with certain covenants contained in our 2003 Senior Credit Agreement, our Euro Notes and the indentures relating to our outstanding trust preferred securities. You should not consider EBITDA to be an alternative to net earnings determined in accordance with U.S. GAAP or to cash flow from operations, investing activities or financing activities. In addition, not all funds depicted by EBITDA are available for management’s discretionary use. For example, a substantial portion of such funds are subject to contractual restrictions and functional requirements for debt service, to fund necessary capital expenditures and to meet other commitments from time to time as described in the Company’s 2004 Annual Report on Form 20-F. EBITDA, as calculated, may not be comparable to similarly titled measures

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

reported by other companies. A reconciliation of EBITDA to cash flow provided by operating activities is shown below:

	Six Months			Six Months
	Ended			Ended
	June 30, 2005			June 30, 2004
Total EBITDA	$	579,416		$	524,693
Interest expense (net of interest income)		(84,927	)		(92,022	)
Income tax expense		(148,517	)		(126,262	)
Change in deferred taxes, net		20,546			16,029
Changes in operating assets and liabilities		(98,653	)		23,927
Cash inflow from Hedging		—			4,422
Other items, net		255			85
Net cash provided by operating activities	$	268,120		$	350,872

Recently Issued Accounting Standards

In December 2004, the Financial Accounting Standards Board issued its final standard on accounting for share-based payments (SBP), SFAS No. 123R (revised 2004), Share-Based Payment (SFAS 123R), that requires companies to expense the cost of employee stock options and similar awards. SFAS 123R requires determining the cost that will be measured at fair value on the date of the SBP awards based upon an estimate of the number of awards expected to vest. There will be no right of reversal of cost if the awards expire without being exercised. Fair value of the SBP awards will be estimated using an option-pricing model that appropriately reflects the specific circumstances and economics of the awards. Compensation cost for the SBP awards will be recognized as they vest. Such cost is not deductible under German tax law.

We will have three alternative transition methods, each having a different reporting implication. The effective date is for interim and annual periods beginning after June 15, 2005. On April 14, 2005, the Securities and Exchange Commission announced the adoption of a new rule that amends the compliance dates for SFAS 123R. The Commission’s new rule allows companies to implement SFAS 123R at the beginning of their next fiscal year instead of the next reporting period that begins after June 15, 2005. We are in the process of determining the transition method that we will adopt and the potential impact on our consolidated financial statements.

In March 2005, the Financial Accounting Standards Board issued Interpretation No. 47 (“FIN 47”) that clarifies that the term conditional asset retirement obligation as used in FASB Statement No. 143, Accounting for Asset Retirement Obligations, (“SFAS 143”) refers to a legal obligation to perform an asset retirement activity in which the timing and (or) method of settlement are conditional on a future event that may or may not be within the control of the entity. The obligation to perform the asset retirement activity is unconditional even though uncertainty exists about the timing and (or) method of settlement. Thus, the timing and (or) method of settlement may be conditional on a future event. Accordingly, an entity is required to recognize a liability for the fair value of a conditional asset retirement obligation if the fair value of the liability can be reasonably estimated. The fair value of a liability for the conditional asset retirement obligation should be recognized when incurred – generally upon acquisition, construction, or development and (or) through the normal operation of the asset. Uncertainty about the timing and (or) method of settlement of a conditional asset retirement obligation should be factored into the measurement of the liability when sufficient information exists. SFAS 143 acknowledges that in some cases, sufficient information may not be available to

PART I

FINANCIAL INFORMATION

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the three and six months ended June 30, 2005 and 2004 – (Continued)

reasonably estimate the fair value of an asset retirement obligation. This Interpretation also clarifies when an entity would have sufficient information to reasonably estimate the fair value of an asset retirement obligation. This Interpretation is effective for fiscal years ending after December 15, 2005. We are in the process of determining the potential impact, if any, on our consolidated financial statements.

PART 1

FINANCIAL INFORMATION

ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In conjunction with the anticipated acquisition of Renal Care Group, Inc. and the forecasted variable rate interest payments for its financing we entered into forward starting interest rate swaps in the notional amount of $1.5 billion in June and July 2005. These instruments, designated as cash flow hedges, effectively convert forecasted variable rate interest payments into fixed rate interest payments with an average fixed rate of 4.185% plus an applicable margin. These swaps are denominated in U.S. dollars and expire at various dates in 2010 and 2011. At June 30, 2005, the effects of these cash flow hedges have been recorded in other comprehensive income. Fair value of these instruments at June 30, 2005 is $0.044 million.

For additional information, see Item 11 in the 2004 Form 20-F, “Quantitative and Qualitative Disclosures About Market Risk”.

PART 1

FINANCIAL INFORMATION

ITEM 4

CONTROLS AND PROCEDURES

The Company’s management, including the Chief Executive Officer and Chief Financial Officer, have conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report, as contemplated by Securities Exchange Act Rule 13a-14. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the disclosure controls and procedures are effective in ensuring that all material information required to be filed in this quarterly report has been made known to them in a timely fashion. During the past fiscal quarter, there have been no significant changes in internal controls, or in factors that could significantly affect internal controls.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

Commercial Litigation

We were formed as a result of a series of transactions pursuant to the Agreement and Plan of Reorganization (the “Merger”) dated as of February 4, 1996 by and between W.R. Grace & Co. and Fresenius AG. At the time of the Merger, a W.R. Grace & Co. subsidiary known as W.R. Grace & Co.-Conn. had, and continues to have, significant potential liabilities arising out of product-liability related litigation, pre-Merger tax claims and other claims unrelated to NMC, which was W.R. Grace & Co.’s dialysis business prior to the Merger. In connection with the Merger, W.R. Grace & Co.-Conn. agreed to indemnify us, FMCH, and NMC against all liabilities of W.R. Grace & Co., whether relating to events occurring before or after the Merger, other than liabilities arising from or relating to NMC’s operations. W.R. Grace & Co. and certain of its subsidiaries filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Grace Chapter 11 Proceedings”) on April 2, 2001.

Pre-Merger tax claims or tax claims that would arise if events were to violate the tax-free nature of the Merger, could ultimately be our obligation. In particular, W.R. Grace & Co. has disclosed in its filings with the Securities and Exchange Commission that: its tax returns for the 1993 to 1996 tax years are under audit by the Internal Revenue Service (the “Service”); W.R. Grace & Co. has received the Service’s examination report on tax periods 1993 to 1996; that during those years W.R. Grace & Co. deducted approximately $122 million in interest attributable to corporate owned life insurance (“COLI”) policy loans; that W.R. Grace & Co. has paid $21 million of tax and interest related to COLI deductions taken in tax years prior to 1993; that a U.S. District Court ruling has denied interest deductions of a taxpayer in a similar situation. In October 2004, W.R. Grace & Co. obtained bankruptcy court approval to settle its COLI claims with the Service. In January 2005, W.R. Grace & Co., FMCH and Sealed Air Corporation executed a settlement agreement with respect to the Service’s COLI-related claims and other tax claims. On April 14, 2005, W.R. Grace & Co. paid the Service approximately $90 million in connection with taxes owed for the tax periods 1993 to 1996 pursuant to a bankruptcy court order directing W.R. Grace & Co. to make such payment. Subject to certain representations made by W.R. Grace & Co., the Company and Fresenius AG, W.R. Grace & Co. and certain of its affiliates had agreed to indemnify us against this and other pre-Merger and Merger-related tax liabilities.

Prior to and after the commencement of the Grace Chapter 11 Proceedings, class action complaints were filed against W.R. Grace & Co. and FMCH by plaintiffs claiming to be creditors of W.R. Grace & Co.- Conn., and by the asbestos creditors’ committees on behalf of the W.R. Grace & Co. bankruptcy estate in the Grace Chapter 11 Proceedings, alleging among other things that the Merger was a fraudulent conveyance, violated the uniform fraudulent transfer act and constituted a conspiracy. All such cases have been stayed and transferred to or are pending before the U.S. District Court as part of the Grace Chapter 11 Proceedings.

In 2003, we reached agreement with the asbestos creditors’ committees on behalf of the W.R. Grace & Co. bankruptcy estate and W.R. Grace & Co. in the matters pending in the Grace Chapter 11 Proceedings for the settlement of all fraudulent conveyance and tax claims against it and other claims related to us that arise out of the bankruptcy of W.R. Grace & Co. Under the terms of the settlement agreement as amended (the “Settlement Agreement”), fraudulent conveyance and other claims raised on behalf of asbestos claimants will be dismissed with prejudice and we will receive protection against existing and potential future W.R. Grace & Co. related claims, including fraudulent conveyance and asbestos claims, and indemnification against income tax claims related to the non-NMC members of the W.R. Grace & Co. consolidated tax group upon confirmation of a W.R. Grace & Co. bankruptcy reorganization plan that contains such provisions. Under the Settlement Agreement, we will pay a total of $115 million to the W.R. Grace & Co. bankruptcy estate, or as otherwise directed by the Court, upon plan confirmation. No admission of liability has been or will be made. The Settlement Agreement has been approved by the U.S. District Court. Subsequent to the Merger, W.R. Grace & Co. was involved in a multi-step transaction involving Sealed Air Corporation (“Sealed Air”,

PART II

OTHER INFORMATION – (Continued)

formerly known as Grace Holding, Inc.). We are engaged in litigation with Sealed Air to confirm our entitlement to indemnification from Sealed Air for all losses and expenses incurred by the Company relating to pre-Merger tax liabilities and Merger-related claims. Under the Settlement Agreement, upon confirmation of a plan that satisfies the conditions of our payment obligation, this litigation will be dismissed with prejudice.

On April 4, 2003, FMCH filed a suit in the United States District Court for the Northern District of California, Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that it does not infringe on patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against it for alleged infringement of Baxter’s patents. In general, the alleged patents concern touch screens, conductivity alarms, power failure data storage, and balance chambers for hemodialysis machines. Baxter has filed counterclaims against FMCH seeking monetary damages and injunctive relief, and alleging that it willfully infringed on Baxter’s patents. FMCH believes its claims are meritorious, although the ultimate outcome of any such proceedings cannot be predicted at this time and an adverse result could have a material adverse effect on our business, financial condition, and results of operations.

Other Litigation and Potential Exposures

In April 2005, FMCH received a subpoena from the U.S. Department of Justice, Eastern District of Missouri, in connection with a joint civil and criminal investigation. The subpoena requires production of a broad range of documents relating to the our operations, with specific attention to documents related to clinical quality programs, business development activities, medical director compensation and physician relations, joint ventures and anemia management programs. We are cooperating with the government’s requests for information. An adverse determination in this investigation could have a material adverse effect on our business, financial condition and results of operations.

In October 2004, FMCH and its Spectra Renal Management subsidiary received subpoenas from the U.S. Department of Justice, Eastern District of New York in connection with a civil and criminal investigation, which requires production of a broad range of documents relating to our operations, with specific attention to documents relating to laboratory testing for parathyroid hormone (“PTH”) levels and vitamin D therapies. We are cooperating with the government’s requests for information. While we believe that we have complied with applicable laws relating to PTH testing and use of vitamin D therapies, an adverse determination in this investigation could have a material adverse effect on our business, financial condition, and results of operations.

From time to time, we are a party to or may be threatened with other litigation, claims or assessments arising in the ordinary course of our business. Management regularly analyzes current information including, as applicable, our defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.

We, like other health care providers, conduct our operations under intense government regulation and scrutiny. We must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. We must also comply with the Anti-Kickback Statute, the False Claims Act, the Stark Statute, and other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from our interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “whistle blower” actions. By virtue of this regulatory environment, as well as our corporate integrity agreement with the government, our business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, investigative demands, subpoenas, other inquiries,

PART II

OTHER INFORMATION – (Continued)

claims and litigation relating to our compliance with applicable laws and regulations. We may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal.

We operate many facilities throughout the United States. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. We rely upon our management structure, regulatory and legal resources, and the effective operation of our compliance program to direct, manage and monitor the activities of these employees. On occasion, we may identify instances where employees, deliberately or inadvertently, have submitted inadequate or false billings. The actions of such persons may subject us and our subsidiaries to liability under the Anti-Kickback Statute, the Stark Statute and the False Claims Act, among other laws.

Physicians, hospitals and other participants in the health care industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker’s compensation or related claims, many of which involve large claims and significant defense costs. We have been and are currently subject to these suits due to the nature of our business and expect that those types of lawsuits may continue. Although we maintain insurance at a level which we believe to be prudent, we cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against us or any of our subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of our operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on our reputation and business.

We have also had claims asserted against us and have had lawsuits filed against us relating to businesses that we have acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. When appropriate, we have asserted our own claims, and claims for indemnification. A successful claim against us or any of our subsidiaries could have a material adverse effect upon us and the results of our operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on our reputation and business.

Accrued Special Charge for Legal Matters

At December 31, 2001, we recorded a pre-tax special charge of $258 million to reflect anticipated expenses associated with the defense and resolution of pre-Merger tax claims, Merger-related claims, and commercial insurer claims (see Note 7 to the consolidated financial statements in this report). The costs associated with the Settlement Agreement and settlements with insurers have been charged against this accrual. While we believe that our remaining accruals reasonably estimate our currently anticipated costs related to the continued defense and resolution of the remaining matters, no assurances can be given that our actual costs incurred will not exceed the amount of this accrual.

PART II

OTHER INFORMATION – (Continued)

Item 4. Submission of Matters to a Vote of Security Holders

Seven resolutions were presented for approval at the Annual General Meeting by the Ordinary shareholders, as follows:

Voting results of the Ordinary Shareholders Meeting

		Votes
	Resolution	In Favor		Opposed		Abstention
1	Resolution on appropriation of the distributable profit		44,603,652		50,761		7,623
2	Resolution to approve the activities of the Management Board during the fiscal year 2004		44,603,429		49,587		9,020
3	Resolution to approve the activities of the Supervisory Board during the fiscal year 2004		45,602,669		50,250		9,117
4	Selection of the auditor for the fiscal year 2005		44,566,922		51,030		44,084
5	By-Election of the Supervisory Board		44,603,419		49,533		9,084
6	Resolution to be adopted on an adjustment of fees for members of the Supervisory Board and a corresponding modification of the Articles of Association		44,311,215		112,874		237,947
7	Resolution concerning revocation of the previous authorized Capital I and for the creation of new authorized Capital I and a corresponding modification of the Articles of Association		44,179,540		241,255		241,241

Voting results of the Separate Preference Shareholders Meeting

		Votes
	Resolution	In Favor		Opposed		Abstention
1	Consent to a resolution of the Ordinary General Meeting of Fresenius Medical Care Aktiengesellschaft of the same day concerning revocation of the previous authorized Capital I and the creation of new authorized Capital I and a corresponding modification of the Articles of Association		5,404,168		815		893

Item 6. Exhibits

Exhibit No.			Item
	10	.1	Amended Memorandum and Articles of Association (Satzung) of Fresenius Medical Care AG dated May 24, 2005 and effective June 22, 2005.
	31	.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	31	.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	32	.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (This exhibit accompanies this report as required by the Sarbanes-Oxley Act of 2002 and is not to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Fresenius Medical Care Aktiengesellschaft

By: /s/ Dr. Ben Lipps

Name: Dr. Ben Lipps

Title: Chief Executive Officer and

Chairman of the Management Board

By: /s/ Lawrence A. Rosen

Name: Lawrence A. Rosen Title: Chief Financial Officer

DATE: August 5, 2005

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · FRESENIUS MEDICAL CARE CORP